Engineered T cell receptors targeting EGFR antigens and methods of use

JP2023548556A5Pending Publication Date: 2024-11-12BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527029
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-05
Filing Date
2021-11-04
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There is a need for engineered T cell receptors (TCRs) that specifically target cancer-specific antigens, particularly those containing the L858R mutation in the EGFR gene, to enhance the efficacy of cancer treatment by improving the tumor-specificity and killing capacity of genetically modified T cells.

Method used

Development of engineered TCRs that recognize EGFR neoantigens with the L858R mutation and are restricted to HLA class I A31 and A33 allotypes, comprising specific amino acid sequences in the CDR3 regions, which can be used to modify T cells for targeted cancer therapy.

Benefits of technology

The engineered TCRs enhance the ability of T cells to recognize and kill cancer cells expressing the EGFR L858R mutation, potentially increasing overall survival, reducing tumor burden, and preventing cancer recurrence or metastasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000084_0000
    Figure 00000084_0000
  • Figure 00000084_0001
    Figure 00000084_0001
  • Figure 00000084_0002
    Figure 00000084_0002
Patent Text Reader

Abstract

The present disclosure provides engineered T cell receptors (TCRs), cells comprising TCRs, and methods of making and using TCRs. The present disclosure relates to a TCR that specifically recognizes an EGFR neoantigen comprising the L858R mutation and restricted to the HLA class I A31 and A33 allotypes. Accordingly, an aspect of the present disclosure relates to a polypeptide comprising an antigen-binding variable region comprising the amino acid sequence of a CDR3 of the present disclosure or an amino acid sequence having at least 80% sequence identity to the CDR3 of the present disclosure. A further aspect relates to an engineered T cell receptor (TCR) comprising a TCR-b polypeptide and a TCR-a polypeptide, wherein the TCR-b polypeptide comprises the amino acid sequence of a CDR3 of the present disclosure or an amino acid sequence having at least 80% sequence identity to the CDR3 of the present disclosure, and the TCR-a polypeptide comprises the amino acid sequence of a CDR3 of the present disclosure or an amino acid sequence having at least 80% sequence identity to the CDR3 of the present disclosure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 110,116, filed Nov. 5, 2020, which is hereby incorporated by reference in its entirety.

[0002] II. Sequence Listing This application includes a sequence listing submitted in ASCII format, which is hereby incorporated by reference in its entirety. A copy of the ASCII created on Oct. 25, 2021 is named MDACP1244WO_ST25.txt and is 100,085 bytes in size.

[0003] III. Field of the Invention The present invention relates to the field of cancer therapies.

Background Art

[0004] IV. Background Adoptive T-cell therapy is one of the potentially powerful cancer treatments that involves genetically modifying native T cells to make them tumor-specific and enhance their ability to destroy tumor cells. Genetically modified T cells can express chimeric antigen receptors (CARs) or T cell receptors (TCRs) and have shown impressive results in several clinical trials. TCR-manipulated T cells (TCR-T) are highly promising against tumors. The efficacy of TCRs depends on their interaction with the major histocompatibility complex (pMHC), a complex formed by peptides bound to MHC molecules. Intracellular antigens are cleaved into peptide chains and presented by MHC molecules to form pMHCs. Cytoplasmic proteins expressed by class I MHC proteins are mostly defective ribosome translation products and are cleaved into peptide chains by proteolysis. These peptides then bind to class I MHC proteins expressed on the cell surface of all nucleated cells. Some cells, called antigen-presenting cells (APCs), express class II MHC proteins. These cells internalize foreign proteins through endocytosis, cleave them into peptide chains, and bind them to class II MHC proteins. T cell receptors on T cells (which must match the patient's human leukocyte antigen (HLA) alleles) recognize these pMHCs, leading to the killing of cancer cells (human class I MHC proteins are expressed from three gene regions: HLA-A, HLA-B, and HLA-C, and human class II MHC proteins are also expressed from three gene regions: HLA-DR, HLA-DP, and HLA-DQ). Manipulation of TCRs, which are directed towards cancer-specific antigens and useful for cancer treatment, is necessary in this art. [Overview of the project]

[0005] This disclosure provides engineered T cell receptors (TCRs), cells containing TCRs, and methods for producing and using TCRs. This disclosure relates to TCRs that specifically recognize EGFR neoantigens containing the L858R mutation and constrained to HLA class I A31 and A33 allotypes.

[0006] Accordingly, aspects of the present disclosure relate to polypeptides comprising an antigen-binding variable region comprising the amino acid sequence of the present disclosure CDR3 or an amino acid sequence having at least 80% sequence identity to the present disclosure CDR3. Further aspects relate to an engineered T cell receptor (TCR) comprising a TCR-b polypeptide and a TCR-a polypeptide, wherein the TCR-b polypeptide comprises the amino acid sequence of the present disclosure CDR3 or an amino acid sequence having at least 80% sequence identity to the present disclosure CDR3, and the TCR-a polypeptide comprises the amino acid sequence of the present disclosure CDR3 or an amino acid sequence having at least 80% sequence identity to the present disclosure CDR3. Further aspects relate to nucleic acids encoding a TCR-b polypeptide and / or a TCR-a polypeptide comprising the amino acid sequence of the present disclosure or an amino acid sequence having at least 80% sequence identity to the present disclosure CDR3. CDR3 can be CDR3 with SEQ ID NO: 8, 14, 28, 22, 42, 36, 56, 50, 70, 64, 84, or 78. TCR-a CDR3 contains CDRs having amino acid sequences with SEQ ID NO: 14, 22, 36, 50, 64, and 78. TCR-b CDR3 contains CDRs having amino acid sequences with SEQ ID NO: 8, 28, 42, 56, 70, and 84.

[0007] Further aspects relate to nucleic acids encoding the polypeptide and the engineered TCR, nucleic acid vectors comprising one or more nucleic acids of the Disclosure, and cells comprising the polypeptide, engineered TCR and / or nucleic acid of the Disclosure. Compositions comprising the polypeptide, cells, nucleic acid or engineered TCR of the Disclosure are also provided. Further aspects relate to methods for producing engineered cells, comprising the step of transferring the nucleic acid or vector of the Disclosure into cells. Further aspects relate to methods for treating cancer in a subject, comprising the step of administering the polypeptide, composition, cells, nucleic acid or engineered TCR to a subject in need. Methods include methods for reducing tumor burden; methods for lysing cancer cells; methods for killing tumor / cancer cells; methods for increasing overall survival; methods for reducing the risk of developing cancer or tumors; methods for increasing recurrence-free survival; methods for preventing cancer; and / or methods for reducing, eliminating or decreasing the spread or metastasis of cancer, and such methods also include the step of administering the polypeptide, composition, cells, nucleic acid or engineered TCR to a subject in need.

[0008] Further aspects relate to fusion proteins comprising the TCR and CD3-binding regions of this disclosure. In some aspects, the CD3-binding region includes a CD3-specific antigen-binding fragment (Fab), a single-chain variable fragment (scFv), a single-domain antibody, or a single-chain antibody. Exemplary CD3-specific antigen-binding fragments (Fab) are known in the art. For example, US20180222981, incorporated herein by reference, discloses a variable region that specifically binds to CD3 and can be used in aspects of this disclosure. Anti-CD3 antibodies and variable regions are disclosed in US20180117152, also incorporated by reference.

[0009] The nucleic acids of this disclosure include those encoding CDR regions, variable regions, manipulated TCRs, polypeptides, TCR-α polypeptides, TCR-β polypeptides, and fusion proteins as described herein. In some aspects, the nucleic acids include one of SEQ ID NO: 1, 15, 29, 43, 57, or 71, or a fragment thereof. In some aspects, nucleic acids contain nucleotides having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one or a fragment of SEQ ID NO: 1, 15, 29, 43, 57, or 71, or nucleotides having sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein).

[0010] In some aspects, the polypeptides or TCR-a polypeptides of the present disclosure include a CDR3 containing an amino acid sequence having or possessing sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 14, 22, 36, 50, 64, and 78. In some aspects, the polypeptides or TCR-b polypeptides of the present disclosure include a CDR3 comprising an amino acid sequence having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 8, 28, 42, 56, 70, and 84, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein). In some aspects, the polypeptides of this disclosure or the TCR-b polypeptides include a CDR3 having one amino acid sequence among SEQ ID NO: 8, 28, 42, 56, 70, and 84.In some aspects, the manipulated TCR contains a CDR3 having amino acids that have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 14, 22, 36, 50, 64, and 78, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 14, 22, 36, 50, 64, and 78, or TCR-a and SEQ ID The TCR-b polypeptide comprises a CDR3 having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of NO:8, 28, 42, 56, 70, and 84, or a CDR3 having amino acids with sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein).

[0011] In some aspects, nucleic acids have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 14, 22, 36, 50, 64, and 78, or TCR-a polypeptide containing CDR3 containing an amino acid sequence having sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 14, 22, 36, 50, 64, and 78, or SEQ ID The TCR-b polypeptide containing a CDR3 has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of NO:8, 28, 42, 56, 70, and 84, or has sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein).

[0012] In some aspects, the polypeptide or TCR comprises a variable region comprising CDR1, CDR2, and / or CDR3 derived from the TCR-a polypeptide and / or TCR-b polypeptide. In some aspects, the variable region comprises CDR1 having one amino acid sequence among SEQ ID NO: 12, 6, 20, 26, 34, 40, 48, 54, 62, 68, 76, and 82, or having at least 80% sequence identity to one of SEQ ID NO: 12, 6, 20, 26, 34, 40, 48, 54, 62, 68, 76, and 82. In some aspects, the variable region contains a CDR1 having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 12, 6, 20, 26, 34, 40, 48, 54, 62, 68, 76, and 82, or CDR1 having sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom).

[0013] In some aspects, the polypeptide, TCR, or TCR-a polypeptide contains a CDR1 having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 12, 20, 34, 48, 62, and 76, or CDR1 containing an amino acid sequence having sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein). In some aspects, the polypeptide, TCR, or TCR-α polypeptide comprises a CDR1 having one amino acid sequence among SEQ ID NO: 12, 20, 34, 48, 62, and 76. In some aspects, the polypeptide, TCR, or TCR-b polypeptide contains a CDR1 having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 6, 26, 40, 54, 68, and 82, or having sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein). In some aspects, the polypeptide, TCR, or TCR-b polypeptide comprises a CDR1 having one amino acid sequence among SEQ ID NO: 6, 26, 40, 54, 68, and 82.

[0014] In some aspects, the manipulated TCR contains CDR1 having amino acids with sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 12, 20, 34, 48, 62, and 76, or TCR-a and SEQ ID The TCR-b polypeptide comprises a CDR1 having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of NO:6, 26, 40, 54, 68, and 82, or a CDR1 having amino acids with sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein). In some aspects, the manipulated TCR comprises TCR-a polypeptide containing a CDR1 having one amino acid sequence among SEQ ID NO: 12, 20, 34, 48, 62, and 76, and TCR-b polypeptide containing a CDR1 having one amino acid sequence among SEQ ID NO: 6, 26, 40, 54, 68, and 82.

[0015] In some aspects, nucleic acids have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 12, 20, 34, 48, 62, and 76, or TCR-a polypeptide containing CDR1 having sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 12, 20, 34, 48, 62, and 76, or TCR-a polypeptide containing CDR1 and / or SEQ ID The TCR-b polypeptide containing CDR1 has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of NO:6, 26, 40, 54, 68, and 82, or has sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein). In some aspects, nucleic acids encode TCR-a polypeptides containing CDR1 with one amino acid sequence among SEQ ID NO: 12, 20, 34, 48, 62, and 76, and / or TCR-b polypeptides containing CDR1 with one amino acid sequence among SEQ ID NO: 6, 26, 40, 54, 68, and 82.

[0016] In some aspects, the polypeptide, TCR-a, or TCR-b may include a variable region. The variable region may include a CDR2 having one amino acid sequence among SEQ ID NO: 13, 7, 21, 27, 35, 41, 49, 55, 63, 69, 77, and 83, or having at least 80% sequence identity to one of SEQ ID NO: 13, 7, 21, 27, 35, 41, 49, 55, 63, 69, 77, and 83. In some aspects, the variable region includes a CDR2 having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 13, 7, 21, 27, 35, 41, 49, 55, 63, 69, 77, and 83, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein).

[0017] In some aspects, the polypeptides or TCR-a polypeptides of the present disclosure include a CDR2 having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 13, 21, 35, 49, 63, and 77, or having sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein). In some aspects, the polypeptides of this disclosure or the TCR-α polypeptides include a CDR2 having one amino acid sequence among SEQ ID NO: 13, 21, 35, 49, 63, and 77. In some aspects, the polypeptides or TCR-b polypeptides of the present disclosure include a CDR2 having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 7, 27, 41, 55, 69, and 83, or a CDR2 containing an amino acid sequence having sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein). In some aspects, the polypeptides of this disclosure or the TCR-b polypeptides include a CDR2 having one amino acid sequence among SEQ ID NO: 7, 27, 41, 55, 69, and 83.

[0018] In some aspects, the manipulated TCR contains a CDR2 having amino acids with sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 13, 21, 35, 49, 63, and 77, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 13, 21, 35, 49, 63, and 77, and SEQ ID The TCR-b polypeptide contains a CDR2 having sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of NO:7, 27, 41, 55, 69, and 83, or a CDR2 containing amino acids having sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein). In some aspects, the manipulated TCR comprises TCR-a polypeptide containing a CDR2 having one amino acid sequence among SEQ ID NO: 13, 21, 35, 49, 63, and 77, and TCR-b polypeptide containing a CDR2 having one amino acid sequence among SEQ ID NO: 7, 27, 41, 55, 69, and 83.

[0019] In some aspects, nucleic acids have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of SEQ ID NO: 13, 21, 35, 49, 63, and 77, or TCR-a polypeptide containing CDR2 and / or SEQ ID The TCR-b polypeptide containing a CDR2 has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein) to one of NO:7, 27, 41, 55, 69, and 83, or has sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range derivable therein). In some aspects, the nucleic acid encodes a TCR-a polypeptide containing a CDR2 having one of the amino acid sequences among SEQ ID NO: 13, 21, 35, 49, 63, and 77, and / or a TCR-b polypeptide containing a CDR2 having one of the amino acid sequences among SEQ ID NO: 7, 27, 41, 55, 69, and 83.

[0020] In some aspects, the variable region contains an amino acid sequence that has at least 70% sequence identity with one of SEQ ID NO: 10, 4, 18, 24, 32, 38, 46, 52, 60, 66, 74, and 80. In some aspects, the variable region contains an amino acid sequence that has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 10, 4, 18, 24, 32, 38, 46, 52, 60, 66, 74, and 80, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 10, 4, 18, 24, 32, 38, 46, 52, 60, 66, 74, and 80. In some aspects, the variable region contains one amino acid sequence from among SEQ ID NO: 10, 4, 18, 24, 32, 38, 46, 52, 60, 66, 74, and 80. In some aspects, the TCR-a variable region contains an amino acid sequence having at least 70% sequence identity with one of SEQ ID NO: 10, 18, 32, 46, 60, and 74. In some aspects, the TCR-a variable region contains amino acid sequences that have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 10, 18, 32, 46, 60, and 74, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom). In some aspects, the TCR-α variable region contains one amino acid sequence from among SEQ ID NO: 10, 18, 32, 46, 60, and 74.In some aspects, the TCR-β variable region contains an amino acid sequence that has at least 70% sequence identity with one of SEQ ID NO: 4, 24, 38, 52, 66, and 80. In some aspects, the TCR-b variable region contains amino acid sequences that have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 4, 24, 38, 52, 66, and 80, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 4, 24, 38, 52, 66, and 80. In some aspects, the TCR-β variable region contains one amino acid sequence from among SEQ ID NO: 4, 24, 38, 52, 66, and 80.

[0021] In some aspects, the polypeptide includes the T cell receptor alpha (TCR-a) variable region. In some aspects, the variable region includes CDR1, CDR2, and / or CDR3. In some aspects, the polypeptide includes the TCR-a variable and constant regions. In some aspects, the polypeptide further includes a signal peptide. In some aspects, the signal peptide includes an amino acid sequence having at least 80% identity to one of SEQ ID NO: 11, 5, 19, 25, 33, 39, 47, 53, 61, 67, 75, and 81. In some aspects, the signal peptide contains an amino acid sequence that has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 11, 5, 19, 25, 33, 39, 47, 53, 61, 67, 75, and 81, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to one of SEQ ID NO: 11, 5, 19, 25, 33, 39, 47, 53, 61, 67, 75, and 81, or contains an amino acid sequence that has sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom). In some aspects, the signal peptide contains one amino acid sequence from among SEQ ID NO: 11, 5, 19, 25, 33, 39, 47, 53, 61, 67, 75, and 81.

[0022] The aspects of the TCR of this disclosure relate to a TCR comprising TCR-a polypeptides and TCR-b polypeptides, wherein CDR1, CDR2, and CDR3 of the TCR-a polypeptide comprise amino acid sequences of SEQ ID NO: 12, 13, and 14, respectively, and CDR1, CDR3, and CDR3 of the TCR-b polypeptide comprise amino acid sequences of SEQ ID NO: 6, 7, and 8, respectively. In some aspects, the TCR comprises TCR-a polypeptides and TCR-b polypeptides, wherein CDR1, CDR2, and CDR3 of the TCR-a polypeptide comprise amino acid sequences of SEQ ID NO: 20, 21, and 22, respectively, and CDR1, CDR3, and CDR3 of the TCR-b polypeptide comprise amino acid sequences of SEQ ID NO: 26, 27, and 28, respectively. In some aspects, TCR comprises TCR-a polypeptides and TCR-b polypeptides, wherein CDR1, CDR2, and CDR3 of TCR-a polypeptides contain amino acid sequences with SEQ ID NO: 34, 35, and 36, respectively, and CDR1, CDR3, and CDR3 of TCR-b polypeptides contain amino acid sequences with SEQ ID NO: 40, 41, and 42, respectively. In some aspects, TCR comprises TCR-a polypeptides and TCR-b polypeptides, wherein CDR1, CDR2, and CDR3 of TCR-a polypeptides contain amino acid sequences with SEQ ID NO: 48, 49, and 50, respectively, and CDR1, CDR3, and CDR3 of TCR-b polypeptides contain amino acid sequences with SEQ ID NO: 54, 55, and 56, respectively. In some aspects, TCR comprises TCR-a polypeptides and TCR-b polypeptides, wherein CDR1, CDR2, and CDR3 of TCR-a polypeptide contain amino acid sequences of SEQ ID NO: 62, 63, and 64, respectively, and CDR1, CDR3, and CDR3 of TCR-b polypeptide contain amino acid sequences of SEQ ID NO: 68, 69, and 70, respectively.In some aspects, TCR comprises TCR-a polypeptides and TCR-b polypeptides, wherein CDR1, CDR2, and CDR3 of TCR-a polypeptide contain amino acid sequences of SEQ ID NO: 76, 77, and 78, respectively, and CDR1, CDR3, and CDR3 of TCR-b polypeptide contain amino acid sequences of SEQ ID NO: 82, 83, and 84, respectively.

[0023] In some aspects, the TCR-a polypeptide contains the amino acid sequence of SEQ ID NO:9 or an amino acid sequence that has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to SEQ ID NO:9, and the TCR-b polypeptide contains the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:3 contains amino acid sequences that have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom), or contains amino acid sequences that have sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom).In some aspects, the TCR-a polypeptide contains the amino acid sequence of SEQ ID NO:17 or an amino acid sequence that has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to SEQ ID NO:17, and the TCR-b polypeptide contains the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:23 contains an amino acid sequence that has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom), or contains an amino acid sequence that has sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom).In some aspects, the TCR-a polypeptide contains the amino acid sequence of SEQ ID NO:31 or an amino acid sequence that has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to SEQ ID NO:31, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom), and the TCR-b polypeptide contains the amino acid sequence of SEQ ID NO:37 or SEQ ID NO:37 contains amino acid sequences that have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom), or contains amino acid sequences that have sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom).In some aspects, the TCR-a polypeptide contains the amino acid sequence of SEQ ID NO:45 or an amino acid sequence that has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to SEQ ID NO:45, or at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom), and the TCR-b polypeptide contains the amino acid sequence of SEQ ID NO:51 or SEQ ID NO:51 contains amino acid sequences that have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom), or contains amino acid sequences that have sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom).In some aspects, the TCR-a polypeptide contains the amino acid sequence of SEQ ID NO: 59 or an amino acid sequence that has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to SEQ ID NO: 59, and the TCR-b polypeptide contains the amino acid sequence of SEQ ID NO: 65 or SEQ ID NO:65 contains amino acid sequences that have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom), or contains amino acid sequences that have sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom).In some aspects, the TCR-a polypeptide contains the amino acid sequence of SEQ ID NO:73 or has sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) to SEQ ID NO:73, or contains an amino acid sequence that has sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom), and the TCR-b polypeptide contains the amino acid sequence of SEQ ID NO:79 or SEQ ID NO:79 contains amino acid sequences that have sequence identity of 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom) or contains amino acid sequences that have sequence identity of at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% (or any range that can be derived therefrom).

[0024] In some aspects, the TCR is modified or chimeric. In some aspects, the variable region of the TCR is fused to a TCR constant region that is different from the constant region of the cloned TCR that specifically binds to the peptide of this disclosure.

[0025] In some aspects, the TCR-a polypeptide and the TCR-b polypeptide are functionally linked. The term “functionally linked” can refer to a covalent bond, such as a peptide bond (e.g., two elements are polypeptides and lie on the same polypeptide), or a non-covalent bond, such as a van der Waals force (e.g., two polypeptides having some degree of specific binding affinity to each other). In some aspects, the TCR-a polypeptide and the TCR-b polypeptide are functionally linked via a peptide bond. In some aspects, the TCR-a polypeptide and the TCR-b polypeptide lie on the same polypeptide, with TCR-b located near the amino region of TCR-a. In some aspects, the TCR-a polypeptide and the TCR-b polypeptide lie on the same polypeptide, with TCR-a located near the amino region of TCR-b. The polypeptides or TCRs of this disclosure may be further defined as single-stranded TCRs. A TCR may include a linker between the TCR-a polypeptide and the TCR-b polypeptide. The linker may include glycine and serine residues. In some aspects, the linker consists only of glycine and serine residues (glycine-serine linker). The linker can be a mobile linker. Exemplary mobile linkers include glycine polymers (G)n and glycine-serine polymers (e.g., including (GS)n, (GSGGS-SEQ ID NO:86)n, (G4S)n and (GGGS-SEQ ID NO:87)n, where n is at least an integer of 1). In some aspects, n is at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (or any range derivable therein), at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (or any range derivable therein), or just 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (or any range derivable therein). Glycine-alanine polymers, alanine-serine polymers, and other mobile linkers known in the art may be used as linkers in the polypeptides of this disclosure.Exemplary linkers can include, or consist of, GGSG (SEQ ID NO:88), GGSGG (SEQ ID NO:89), GSGSG (SEQ ID NO:90), GSGGG (SEQ ID NO:91), GGGSG (SEQ ID NO:92), GSSSG (SEQ ID NO:93), etc. Further linkers useful in the polypeptides and TCRs of the present disclosure are described herein. When the first region is attached to the carboxy terminus of the second region, the first region is carboxy proximal to the second region. Additional amino acid residues may be present intervening between the first and second regions. Thus, these regions need not be directly adjacent unless specifically specified as having no intervening amino acid residues. The term "amino proximal" is similarly defined as the first region being amino proximal to the second region when the first region is attached to the amino terminus of the second region. Similarly, additional amino acid residues may be present intervening between the first and second regions unless otherwise specified.

[0026] CDRs can also include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 16, 18, 19, 20, 21, 22, 23 or more (or any range derivable therein) consecutive amino acid residues adjacent to one or both sides of a particular CDR sequence in relation to the variable region of a TCR-a or TCR-b polypeptide; thus, one or more additional amino acids may be present at the N-terminus or C-terminus of a particular CDR sequence, such as those shown in SEQ ID NO:10, 4, 18, 24, 32, 38, 46, 52, 60, 66, 74 and 80. Alternatively, or in combination, a CDR can also be a fragment of a CDR described herein and may lack at least 1, 2, 3, 4 or 5 amino acids from the C-terminus or N-terminus of a particular CDR sequence.

[0027] In some aspects, the TCR or fusion protein is conjugated to a detection or therapeutic agent. In some aspects, the agent includes a fluorescent molecule, a radioactive molecule, or a toxin. In some aspects, the TCR or fusion protein is conjugated to an agent described herein.

[0028] In some aspects, the nucleic acid includes TCR-a (TRA) and TCR-b (TRB) genes. In some aspects, the nucleic acid is polycistronic. In some aspects, the nucleic acid includes a 2A-cleavable linker, such as an internal ribosome entry site (IRES) or a P2A linker. In some aspects, the nucleic acid includes cDNA encoding the TCR-a and / or TCR-b genes. In some aspects, the nucleic acid further encodes a polypeptide including a CD3-binding region. In some aspects, the CD3-binding region includes a CD3-specific antigen-binding fragment (Fab), a single-chain variable fragment (scFv), a single-domain antibody, or a single-chain antibody.

[0029] In some aspects, the vector contains both the TCR-a and TCR-b genes. In some aspects, the vector contains a promoter that directs the expression of nucleic acids. In some aspects, the promoter contains a mouse stem cell virus (MSCV) promoter. In some aspects, the cells contain stem cells, progenitor cells, immune cells, or natural killer (NK) cells. In some aspects, the cells contain hematopoietic stem cells or hematopoietic progenitor cells, T cells, cells differentiated from mesenchymal stem cells (MSCs), or induced pluripotent stem cells (iPSCs). In some aspects, the cells are isolated from or derived from peripheral blood mononuclear cells (PBMCs). In some aspects, the T cells contain cytotoxic T lymphocytes (CTLs), CD8+ T cells, CD4+ T cells, invariant NK T (iNKT) cells, gamma-delta T cells, NKT cells, or regulatory T cells. In some aspects, the cells are isolated from cancer patients. In some aspects, the cells are isolated from non-cancer patients. In some cases, the cells are isolated from healthy patients. In some cases, the cells are frozen or not frozen. In some cases, the cells are in cell culture. In some cases, the cells lack endogenous expression of the TCR gene. In some cases, the cells further contain chimeric antigen receptors (CARs).

[0030] In some aspects, the composition has been determined to be serum-free, mycoplasma-free, endotoxin-free, and / or sterile. In some aspects, the method further comprises the steps of culturing cells in a culture medium, incubating cells under conditions that allow cell division, screening cells, and / or freezing cells.

[0031] In some aspects, cancer includes lung cancer. In some aspects, the subject has been diagnosed with cancer, such as lung cancer. In some aspects, cancer includes solid tumors. In some aspects, the subject has previously received treatment for cancer. In some aspects, the subject has been determined to be resistant to the previous treatment. In some aspects, this method further includes administering further treatment. In some aspects, the subject is a mammal. In some aspects, the subject includes laboratory test animals such as mice, rats, rabbits, dogs, cats, horses, or pigs. In some aspects, the subject is human. In some aspects, the subject has been determined to be HLA-A31 or HLA-A33 positive. In some aspects, the subject carries the EGFR L858R mutation. In some aspects, the subject has been determined to have an EGFR protein with the L858R mutation, or to have a gene mutation in the EGFR gene resulting in an EGFR L858R mutant protein. In some contexts, cancer includes EGFR L858R-positive lung cancer.

[0032] In some contexts, lung cancer includes small cell lung cancer, non-small cell lung cancer, metastatic lung cancer, lung nodules, adenosquamous cell carcinoma, large cell neuroendocrine carcinoma, salivary gland type lung cancer, lung carcinoid, or mesothelioma. In some contexts, lung cancers such as small cell lung cancer, non-small cell lung cancer, metastatic lung cancer, lung nodules, adenosquamous cell carcinoma, large cell neuroendocrine carcinoma, salivary gland type lung cancer, lung carcinoid, or mesothelioma are excluded. In some contexts, cancer includes lung adenocarcinoma, non-small cell lung cancer, squamous cell lung cancer, or small cell lung cancer.

[0033] In some aspects, the compositions of this disclosure are formulated as vaccines. In some aspects, the compositions and methods of this disclosure provide prophylactic therapies for the prevention of cancer. In some aspects, the compositions and methods of this disclosure provide therapeutic therapies for treating existing cancers, such as for the treatment of patients with cancer. In some aspects, the compositions further comprise adjuvants. Adjuvants are known in the art and include, for example, TLR agonists and aluminum salts.

[0034] In some aspects, the methods of the present disclosure further include a step of screening cells for one or more cellular characteristics, such as immunogenicity, including TCR expression, integration of nucleic acids encoding the TCR gene, or binding of the TCR to a cancer antigen. In some aspects, the subjects are those having or have been determined to have an EGFR mutation at L858R.

[0035] In some aspects, the method includes the step of administering cells or a composition containing cells, wherein the cells include self-cells. In some aspects, the cells include non-self-cells.

[0036] "Treatment" or "treatment" can mean any treatment of a disease in a mammal, including (i) preventing the disease, i.e., preventing the development of clinical symptoms of the disease by administering a protective composition before the disease is induced; (ii) suppressing the disease, i.e., preventing the development of clinical symptoms of the disease by administering a protective composition after the induced event, but before the clinical appearance or reappearance of the disease; (iii) blocking the disease, i.e., preventing the development of clinical symptoms by administering a protective composition after its initial appearance; and / or (iv) mitigating the disease, i.e., causing regression of clinical symptoms by administering a protective composition after its initial appearance. In some aspects, treatment may exclude the prevention of disease.

[0037] Throughout this application, the term “about” is used in accordance with its plain and common sense in the field of cell and molecular biology to indicate that a value includes the standard deviation of error with respect to the apparatus or method used to determine that value.

[0038] When used with the term "includes," the use of the words "a" or "an" can mean "one," but also coincides with the meanings of "one or more," "at least one," and "one or more."

[0039] As used herein, the terms “or” and “and / or” are used to describe multiple components in combination or mutually exclusive. For example, “x, y, and / or z” could mean “x” alone, “y” alone, “z” alone, “x, y, and z,” “(x and y) or z,” “x or (y and z),” or “x or y or z.” It is particularly intended that x, y, or z may be specifically excluded from the aspect or aspect.

[0040] The words “comprising” (and any form of “comprising,” such as “comprise” and “comprises”), “having” (and any form of “having,” such as “have” and “has”), “including” (and any form of “including,” such as “includes” and “include”), “characterized by” (and any form of “including,” such as “characterized as”), or “containing” (and any form of “containing,” such as “contains” and “contain”) are inclusive or non-restrictive and do not exclude further, unquoted stages of elements or methods.

[0041] The compositions and methods for their use may "contain," "essentially consist of," or "consist of" any of the components or steps disclosed in this application as a whole. The phrase "consist of" excludes any element, step, or component not specified. The phrase "essentially consist of" limits the scope of the described subject matter to those that do not substantially affect the particular material or step and its basic and novel characteristics. The aspects and aspects described in the context of the term "contain" are also intended to be implemented in the context of the terms "consist of" or "essentially consist of."

[0042] Any method in the context of a therapeutic, diagnostic, or physiological purpose or effect may also be described in the language of a “use” claim, such as “use” of any compound, composition, or agent discussed herein, for achieving or carrying out the described therapeutic, diagnostic, or physiological purpose or effect.

[0043] The use of one or more sequences or compositions may be utilized based on any of the methods described herein. Other embodiments are discussed throughout this application. Any embodiment or aspect discussed in relation to one aspect of this disclosure is also applicable to other aspects of this disclosure, and vice versa.

[0044] It is particularly intended that any limitations discussed in relation to one aspect or part of the present invention may apply to any other aspect or part of the present invention. Furthermore, any composition of the present invention may be used in any method of the present invention, and any method of the present invention may be used to prepare or utilize any composition of the present invention. Aspects of the aspects described in the examples may also be implemented elsewhere in different examples or elsewhere in this application, for example, in the context of aspects discussed in the summary of the invention, the detailed description of aspects, the claims, and the legend of the figures.

[0045] Other objects, features, and advantages of the present invention will become apparent from the following detailed description. However, while the detailed description and specific examples illustrate certain aspects and aspects of the present invention, it should be understood that they are merely illustrative, as various modifications and changes within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. [Brief explanation of the drawing]

[0046] The following drawings constitute part of this specification and are included to further illustrate certain aspects of the invention. The invention may be better understood by referring to one or more of these drawings together with the detailed description of the specific embodiments presented herein.

[0047] [Figure 1] TCRA31-1 and TCRA31-2-mediated cytotoxicity. [Figure 2] Interferon-gamma release in response to a dose-defined amount of HVKITDFGR (SEQ ID NO:85) peptide. [Figure 3] IFN-gamma ELISPOT for determining the binding activity of two EGFR-A*3303 TCRs. [Figure 4] Peptide dose setting to determine the killing efficacy of TCR33-32H transduced T cells. [Figure 5] TCR33-32H and TCRA33-32L-mediated cytotoxicity assay. The FACS plot on the left shows PBMCs transduced with TCR construct 33-32H or 33-32L. [Figure 6] TCRA33-32H-mediated cytotoxicity against target cells transduced with the EGFR (L858R) gene. [Figure 7] Killing activity of EGFR-A33 TCR-T cells expressing T33-32H, T33-37-3, or T33-37-4. [Modes for carrying out the invention]

[0048] Detailed description of the invention This disclosure provides a T cell receptor (TCR) that recognizes an EGFR epitope spanning the L858R mutation. This disclosure also provides a nucleotide sequence encoding this TCR, and an expression vector containing this nucleotide sequence that can be used to modify cells, such as peripheral blood mononuclear cells, to produce EGFR-L858R-specific T cells. This disclosure also provides the use of EGFR-L858R-specific T cells for adoptive immunotherapy for cancer patients carrying the EGFR-L858R mutation.

[0049] I. Manipulated T cell receptors T cell receptors contain two distinct polypeptide chains linked by a disulfide bond, called T cell receptor α (TCRα) and β (TCRβ) chains. These α:β heterodimers are structurally very similar to the Fab fragment of immunoglobulin molecules and are responsible for antigen recognition by most T cells. A small number of T cells have another, but structurally similar, receptor consisting of a different pair of polypeptide chains called γ and δ. Both types of T cell receptors differ from membrane-bound immunoglobulins that function as B cell receptors: T cell receptors have only one antigen-binding site, while B cell receptors have two; and T cell receptors are never secreted, while immunoglobulins can be secreted as antibodies.

[0050] Both chains of the T cell receptor have an amino-terminal variable (V) region homologous to the immunoglobulin V domain, a constant (C) region homologous to the immunoglobulin C domain, and a short hinge region containing cysteine ​​residues that form interchain disulfide bonds. Each chain spans the lipid bilayer by a hydrophobic transmembrane domain and terminates with a short cytoplasmic tail.

[0051] The three-dimensional structure of the T cell receptor has been determined. This structure is indeed similar to that of the antibody Fab fragment, as inferred from previous studies on the gene encoding the T cell receptor. The T cell receptor chain folds almost identically to the Fab fragment chain, although the final structure appears slightly shorter and wider. However, there are several distinct differences between the T cell receptor and the Fab fragment. The most striking difference lies in the Cα domain, whose folding differs from that of any other immunoglobulin-like domain. Half of the domain, juxtaposed with the Cβ domain, forms a β-sheet similar to those found in other immunoglobulin-like domains, while the other half of the domain is formed by a loosely packed chain and a short segment of the α-helix. The intramolecular disulfide bond typically links two β-chains in immunoglobulin-like domains, but in the Cα domain, it links a β-chain to this α-helix segment.

[0052] There are also differences in how the domains interact. The interface between the V and C domains of both T cell receptor chains is more extensive than in antibodies, which can reduce the mobility of the hinge junctions between domains. The interaction between the Cα and Cβ domains is distinctive in that it is carbohydrate-assisted, with a sugar group from the Cα domain forming several hydrogen bonds with the Cβ domain. Finally, a comparison of variable binding sites shows that the complementarity-determining region (CDR) loops are fairly closely aligned with the loops of the antibody molecule, but there are some substitutions compared to the antibody molecule's loops. This substitution is particularly pronounced in the Vα CDR2 loop, which is oriented almost perpendicular to the equivalent loop of the antibody V domain as a result of a β chain shift that fixes one end of the loop from one face of the domain to the other. The chain substitution also causes changes in the orientation of two of the Vβ CDR2 loops of the seven Vβ domains whose structures are known. For now, the crystal structures of the seven T cell receptors have been elucidated at this level of resolution.

[0053] The aspect of this disclosure relates to engineered T cell receptors. The term "engineered" means a T cell receptor having a TCR variable region grafted onto the TCR constant region to create chimeric polypeptides that bind to the peptides and antigens of this disclosure. In certain aspects, the TCR is used for cloning, enhancement of expression, detection, or therapeutic control of a construct, but includes intervening sequences not present in the endogenous TCR, such as multicloning sites, linkers, hinge sequences, modified hinge sequences, modified transmembrane sequences, detection polypeptides or molecules, or therapeutic controls that may enable the selection or screening of cells containing the TCR.

[0054] In some aspects, TCRs contain non-TCR sequences. Therefore, certain aspects concern TCRs that have sequences not derived from TCR genes. In some aspects, TCRs are chimeric in that they contain sequences normally found in TCR genes, but also sequences from at least two TCR genes that are not necessarily found together in nature.

[0055] In some aspects, the manipulated TCR of this disclosure includes the following aspects:

[0056] (Table 1) Phases of TCR TIFF2023548556000001.tif227160TIFF2023548556000002.tif226160TIFF2023548556000003.tif244160TIFF2023548556000004.t if242160TIFF2023548556000005.tif142160TIFF2023548556000006.tif206160TIFF2023548556000007.tif231160TIFF20235485560 00008.tif244160TIFF2023548556000009.tif244160TIFF2023548556000010.tif142160TIFF2023548556000011.tif211160TIFF202 3548556000012.tif229160TIFF2023548556000013.tif244160TIFF2023548556000014.tif244160TIFF2023548556000015.tif147160

[0057] II. protein composition As used herein, “protein,” “peptide,” or “polypeptide” means a molecule comprising at least five amino acid residues. As used herein, the term “wild-type” means the endogenous version of a molecule that is naturally present in an organism. In some contexts, the wild-type version of a protein or polypeptide is used; however, in many contexts of this disclosure, a modified protein or polypeptide is used to produce an immune response. The above terms may be used interchangeably. “Modified protein,” “modified polypeptide,” or “variant” means a protein or polypeptide whose chemical structure, in particular its amino acid sequence, has been altered from that of a wild-type protein or polypeptide. In some contexts, a modified / variant protein or polypeptide has at least one modified activity or function (recognizing that a protein or polypeptide may have multiple activities or functions). A modified / variant protein or polypeptide may be modified with respect to one activity or function, but is particularly intended to retain wild-type activity or function in other respects, such as immunogenicity.

[0058] Where a protein is specifically referred to herein, it generally refers to a natural (wild-type) or recombinant (modified) protein, or optionally, a protein from which any signal sequence has been removed. Proteins may be isolated directly from organisms in which they are natural, produced by recombinant DNA / exogenous expression methods, or produced by solid-phase peptide synthesis (SPPS) or other in vitro methods. In certain contexts, there are isolated nucleic acid segments and recombinant vectors incorporating nucleic acid sequences encoding polypeptides (e.g., antibodies or fragments thereof). The term “recombinant” may be used in combination with the name of a polypeptide or a particular polypeptide, but generally refers to a polypeptide produced from a nucleic acid molecule that has been manipulated in vitro or is a replica product of such a molecule.

[0059] In a particular context, the size of a protein or polypeptide (wild-type or modified) is, TIFF2023548556000016.tif48160 amino acid residues or nucleic acid residues or more, and any range thereof that can be derived, or derivatives of the corresponding amino sequences described or referenced herein, may be included, but are not limited to. Polypeptides may be mutated by truncation to be shorter than their corresponding wild-type form, and may also be modified by fusing or conjugating heterologous protein or polypeptide sequences with specific functions (e.g., for targeting or localization, for enhancing immunogenicity, for purification purposes, etc.).

[0060] The polypeptides, proteins, or polynucleotides encoding such polypeptides or proteins of this disclosure may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any range derivable therefrom) or more variant amino acids or nucleic acid substitutions, or at least SEQ ID NO: 1-93 TIFF2023548556000017.tif91160 or more consecutive amino acids or nucleic acids, or any range from which they can be derived, or at most TIFF2023548556000018.tif91160 or more consecutive amino acids or nucleic acids, or any range derivable therefrom, may be at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therefrom) similar, identical, or homologous. In certain contexts, the peptide or polypeptide is a human sequence or based on a human sequence. In certain contexts, the peptide or polypeptide is not naturally occurring and / or is a combination of peptides or polypeptides.

[0061] In some aspects, proteins, polypeptides, or nucleic acids consist of one amino acid or nucleotide with SEQ ID NO: 1-93. This may include TIFF2023548556000019.tif114160 (or any range that can be derived from it).

[0062] In some aspects, proteins, polypeptides, or nucleic acids are SEQ ID NO: 1-93 TIFF2023548556000020.tif114160 (or any range derivable from there) consecutive amino acids or nucleic acids may be included, or at least TIFF2023548556000021.tif114160 (or any range derivable from there) consecutive amino acids or nucleic acids may be included, or at most TIFF2023548556000022.tif114160 (or any range within which can be derived) consecutive amino acids or nucleic acids may be included.

[0063] In some aspects, polypeptides, proteins, or nucleic acids are at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range that can be derived within that range), at most 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83% , 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range that can be derived within that), or just 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, SEQ ID NO: 1-93 are similar, identical, or homologous to 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range that can be derived within that range). TIFF2023548556000023.tif114160 consecutive amino acids (or any range derivable from them) may contain at least TIFF2023548556000024.tif114160 consecutive amino acids (or any range derivable from there) may be, or at most TIFF2023548556000025.tif114 may contain 60 consecutive amino acids (or any range within which can be derived).

[0064] In some situations, one of SEQ ID NO: 1 to 93 TIFF2023548556000026.tif194160TIFF2023548556000027.tif157 Starting at position 159 and SEQ ID NO: one of 1 to 93 TIFF2023548556000028.tif84160TIFF2023548556000029.tif245159TIFF2023548556000030.tif26159 contains (or any range from which can be derived) consecutive amino acids or nucleotides, or at least TIFF2023548556000031.tif84160TIFF2023548556000032.tif245159TIFF2023548556000033.tif26159 contains (or any range from which can be derived) consecutive amino acids or nucleotides, or at most There exists a nucleic acid molecule or polypeptide containing 159 (or any derivable range thereof) consecutive amino acids or nucleotides.

[0065] The disclosed polypeptide is at least TIFF2023548556000037.tif228170 substitutions (or any range that can be derived within them), at most TIFF2023548556000038.tif228170 substitutions (or any range that can be derived within them), or just TIFF2023548556000039.tif may contain 228,170 substitutions (or any range that can be derived from them).

[0066] The substitution is one of the SEQ ID NO:1~93 It may be an amino acid at position 160 (or any range within which it can be derived), and may be substituted with any amino acid, or may be substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.

[0067] Nucleotide sequences of various genes, as well as protein, polypeptide, and peptide sequences, have been previously disclosed and can be found in recognized computerized databases. Two commonly used databases are the Genbank and GenPept databases of the National Center for Biotechnology Information (ncbi.nlm.nih.gov / on the World Wide Web) and the Universal Protein Resource (UniProt; uniprot.org on the World Wide Web). The coding regions of these genes can be amplified and / or expressed using the techniques disclosed herein or as known to those skilled in the art.

[0068] The compositions of this disclosure are intended to contain approximately 0.001 mg to approximately 10 mg of total polypeptides, peptides, and / or proteins per 1 ml. The protein concentrations in the compositions are approximately 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, and 10.0. mg / ml or higher (or any derivable range within that), at least approximately 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 It can be mg / ml or more (or any range within which it can be derived), or at most about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg / ml or more (or any range within which it can be derived).

[0069] The following is a consideration of modifying the amino acid subunits of a protein to produce equivalent or, in some cases, improved second-generation variant polypeptides or peptides. For example, certain amino acids may be used in place of other amino acids in a protein or polypeptide sequence, with or without a significant loss of interaction and binding ability to structures such as, for example, the antigen-binding region of an antibody or a binding site on a substrate molecule. Since the interaction ability and properties of a protein determine its functional activity, it is possible to make specific amino acid substitutions in the protein sequence and in its corresponding DNA coding sequence, while still producing a protein with similar or desirable properties. Thus, the inventors intend that various modifications can be made to the DNA sequence of a protein-coding gene without significantly losing its biological utility or activity.

[0070] The term "functionally equivalent codon" is used herein to mean codons that code for the same amino acid, such as the six different codons for arginine. "Neutral substitution" or "neutral mutation," which refers to a change in a codon that codes for a biologically equivalent amino acid, is also considered.

[0071] The amino acid sequence variants of this disclosure may be substitution variants, insertion variants, or deletion variants. Mutations of the polypeptides of this disclosure may affect 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more (or any range within which can be derived) discontinuous or continuous amino acids in the protein or polypeptide compared to the wild type. A variant may include an amino acid sequence that is at least 50%, 60%, 70%, 80%, or 90% identical to any sequence provided or referenced herein, including all values ​​and ranges in between. A variant may include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more substituted amino acids.

[0072] It is understood that amino acid and nucleic acid sequences may each contain additional residues, such as further N-terminal or C-terminal amino acids, or 5' or 3' sequences, as long as they meet the above criteria, including the maintenance of biological protein activity in which protein expression is involved, and yet may still be essentially identical as described in one of the sequences disclosed herein. Terminal additions are particularly applicable to nucleic acid sequences and may include, for example, various non-coding sequences adjacent to either the 5' or 3' portion of the coding region.

[0073] Deletion variants typically lack one or more residues from the native or wild-type protein. Individual residues may be deleted, or several adjacent amino acids may be deleted. A cleaved protein can be created by introducing a stop codon (by substitution or insertion) into the coding nucleic acid sequence.

[0074] Insertion mutants typically involve the addition of amino acid residues at non-terminal points in a polypeptide. This can include the insertion of one or more amino acid residues. Terminal adducts can also be constructed, and these may include fusion proteins that are polymers or chains of one or more peptides or polypeptides described or referenced herein.

[0075] Substitutional variants typically involve the exchange of one amino acid for another at one or more sites within a protein or polypeptide, and may be designed to modify one or more properties of the polypeptide, with or without loss of other functions or properties. Substitutions may be conservative, meaning one amino acid may be replaced with an amino acid having similar chemical properties. A "conservative amino acid substitution" may involve the exchange of one amino acid class member with another member of the same class. Conservative substitutions are well known in the art and include, for example, the change of alanine to serine, arginine to lysine, asparagine to glutamine or histidine, aspartic acid to glutamic acid, cysteine ​​to serine, glutamine to asparagine, glutamic acid to aspartic acid, glycine to proline, histidine to asparagine or glutamine, isoleucine to leucine or valine, leucine to valine or isoleucine, lysine to arginine, methionine to leucine or isoleucine, phenylalanine to tyrosine, leucine or methionine, serine to threonine, threonine to serine, tryptophan to tyrosine, tyrosine to tryptophan or phenylalanine, and valine to isoleucine or leucine. Conservative amino acid substitutions may include amino acid residues that do not exist in nature and are usually incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptide mimetic molecules or other inverted or reversed amino acid moieties.

[0076] Alternatively, the substitution may be “non-conservative” in such a way that the function or activity of the polypeptide is affected. Non-conservative changes typically involve substituting one amino acid residue with a chemically different residue, such as using a polar or charged amino acid in place of a non-polar or uncharged amino acid, and vice versa. Non-conservative substitutions may involve the exchange of a member from one amino acid class with a member from another class.

[0077] Those skilled in the art can determine suitable variants of polypeptides such as those described herein using well-known techniques. Those skilled in the art can identify suitable regions of a molecule that can be modified without disrupting activity by targeting regions not considered important for activity. Those skilled in the art can also identify conserved amino acid residues and molecular regions among similar proteins or polypeptides. In a further context, regions that may be important for biological activity or structure can undergo conserved amino acid substitutions without significantly altering biological activity or adversely affecting the protein or polypeptide structure.

[0078] When making such modifications, the hydroxyl index of amino acids may be taken into consideration. The hydroxyl profile of a protein is calculated by assigning a numerical value ("hydroxyl index") to each amino acid and then repeatedly averaging these values ​​along the peptide chain. Each amino acid is assigned a value based on its hydrophobic and charge properties. These are isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cysteine ​​(+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (1.6); histidine (-3.2); glutamic acid (-3.5); glutamine (-3.5); aspartic acid (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5). The importance of hydroxyl amino acid indices in conferring interactive biological functions to proteins is generally understood in the art (Kyte et al., J. Mol. Biol. 157:105-131 (1982)). The relative hydroxyl characteristics of amino acids contribute to the resulting secondary structure of proteins or polypeptides, and consequently, this is accepted to define the interaction between proteins or polypeptides and other molecules, such as enzymes, substrates, receptors, DNA, antibodies, and antigens. It is also known that certain amino acids can be substituted with other amino acids having similar hydroxyl indices or scores, and still retain similar biological activity. When making modifications based on hydroxyl indices, in certain aspects this includes substitutions of amino acids with hydroxyl indices within ±2; in some aspects of the present invention this includes substitutions within ±1; and in other aspects of the present invention this includes substitutions within ±0.5.

[0079] It is also understood in the art that similar amino acids can be effectively substituted based on their hydrophilicity. U.S. Patent No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein governed by the hydrophilicity of adjacent amino acids correlates with the biological properties of the protein. In certain contexts, the greatest local average hydrophilicity of a protein governed by the hydrophilicity of adjacent amino acids correlates with its immunogenicity and antigen binding, i.e., with the biological properties of the protein. The following hydrophilic values ​​have been assigned to these amino acid residues: Arginine (+3.0); Lysine (+3.0); Aspartic acid (+3.0±1); Glutamic acid (+3.0±1); Serine (+0.3); Asparagine (+0.2); Glutamine (+0.2); Glycine (0); Threonine (-0.4); Proline (-0.5±1); Alanine (-0.5); Histidine (-0.5); Cysteine ​​(-1.0); Methionine (-1.3); Valine (-1.5); Leucine (-1.8); Isoleucine (-1.8); Tyrosine (-2.3); Phenylalanine (-2.5); and Tryptophan (-3.4). When modifications are made based on similar hydrophilicity values, substitutions may include amino acid substitutions with hydrophilicity values ​​within ±2 in certain aspects, within ±1 in other aspects, and within ±0.5 in yet other aspects. In some cases, epitopes can also be identified from the primary amino acid sequence based on hydrophilicity. These regions are also called "epitope core regions." It is understood that amino acids can be substituted with other amino acids that have similar hydrophilicity values, and still result in biologically and immunologically equivalent proteins.

[0080] Furthermore, those skilled in the art can rethink structure-function studies to identify residues in similar polypeptides or proteins that are important for their activity or structure. From such comparative standpoints, the importance of amino acid residues in proteins corresponding to amino acid residues important for the activity or structure of similar proteins can be predicted. Those skilled in the art can select chemically similar amino acid substitutions for such predicted important amino acid residues.

[0081] Those skilled in the art can also analyze the three-dimensional structure and amino acid sequence in relation to its structure in similar proteins or polypeptides. Considering such information, those skilled in the art can predict the alignment of amino acid residues of the antibody with respect to its three-dimensional structure. Those skilled in the art may choose not to alter amino acid residues predicted to be on the protein surface, as such residues may be involved in important interactions with other molecules. Furthermore, those skilled in the art can construct test variants containing a single amino acid substitution at the position of each desired amino acid residue. These variants can then be screened using standard assay methods for binding and / or activity, thus obtaining information gathered from such routine experiments, which allows those skilled in the art to determine amino acid positions that should be avoided, either alone or in combination with other mutations. Various tools available for determining secondary structure can be found on the World Wide Web at expasy.org / proteomics / protein_structure.

[0082] In some aspects of the present invention, amino acid substitutions are made to (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) modify binding affinity for protein complex formation, (4) modify ligand or antigen binding affinity, and / or (5) confer or modify other physicochemical or functional properties to such polypeptides. For example, one or more amino acid substitutions (conservative amino acid substitutions in certain aspects) may be made in naturally occurring sequences. Substitutions may be made in the portion of an antibody outside the domain that forms an intermolecular contact. In such aspects, conservative amino acid substitutions that do not substantially alter the structural features of the protein or polypeptide (e.g., one or more substituted amino acids that do not disrupt the secondary structure that characterizes the natural antibody) may be used.

[0083] III. Nucleic acids In a particular context, nucleic acid sequences can exist in various forms, including: integrated sequences or isolated segments of recombinant polynucleotides and recombinant vectors encoding one or both strands of an antibody, or fragments thereof, derivatives, mutains, or variants thereof; hybridization probes for identifying, analyzing, mutating, or amplifying polynucleotides encoding polypeptides; polynucleotides sufficient for use as PCR primers or sequencing primers; antisense nucleic acids for inhibiting polynucleotide expression; and the aforementioned complementary sequences as described herein. Nucleic acids encoding epitopes for certain antibodies provided herein are also provided. Nucleic acids encoding fusion proteins containing these peptides are also provided. Nucleic acids can be single-stranded or double-stranded and may include RNA and / or DNA nucleotides as well as their artificial variants (e.g., peptide nucleic acids).

[0084] The term "polynucleotide" refers to a nucleic acid molecule that is either recombinant or isolated from a whole genome. Within the scope of the term "polynucleotide" are oligonucleotides (nucleic acids with a length of 100 residues or less), recombinant vectors, such as plasmids, cosmids, phages, and viruses. A polynucleotide contains a regulatory sequence that, in some respects, is substantially isolated from a native gene or protein-coding sequence. A polynucleotide may be single-stranded (coding or antisense) or double-stranded, and may be RNA, DNA (genomic, cDNA, or synthetic), its analogues, or a combination thereof. Further coding or non-coding sequences may or may not be present within a polynucleotide.

[0085] In this regard, the terms “gene,” “polynucleotide,” or “nucleic acid” are used to mean nucleic acids (including any sequences required for proper transcription, post-translational modification, or localization) that encode proteins, polypeptides, or peptides. As will be understood by those skilled in the art, these terms encompass genome sequences, expression cassettes, cDNA sequences, and smaller genetically engineered nucleic acid segments that express or can be adapted to express proteins, polypeptides, domains, peptides, fusion proteins, and variants. Nucleic acids encoding all or part of a polypeptide may include continuous nucleic acid sequences that encode all or part of such polypeptides. Furthermore, a particular polypeptide may be encoded by nucleic acids, including variants, that have slightly different nucleic acid sequences but still encode the same or substantially similar proteins.

[0086] In certain aspects, there are polynucleotide variants having substantial identity with the sequences disclosed herein; these variants, when compared to the polynucleotide sequences provided herein using the methods described herein (e.g., BLAST analysis with standard parameters), include at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, or more, including all values ​​and ranges between the following: In certain aspects, the isolated polynucleotide comprises a nucleotide sequence encoding a polypeptide having at least 90%, preferably 95%, and more identity with the amino acid sequences described herein over the entire length of the sequence; or a nucleotide sequence complementary to the isolated polynucleotide.

[0087] Nucleic acid segments, regardless of the length of the coding sequence itself, may be combined with other nucleic acid sequences such as promoters, polyadenylation signals, additional restriction enzyme sites, multicloning sites, and other coding segments, and therefore their total length can vary considerably. Nucleic acids can be of any length. They can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1500, 3000, 5000 or more nucleotide lengths, and / or may contain one or more additional sequences, such as regulatory sequences, and / or may be part of a larger nucleic acid, such as a vector. Therefore, nucleic acid fragments of almost any length can be used, and their total length is considered preferable to be limited by the ease of purification and their intended use in the recombinant nucleic acid protocol. In some cases, nucleic acid sequences may encode polypeptide sequences having further heterologous coding sequences, for example, to enable the purification, transport, secretion, or post-translational modification of the polypeptide, or to enable therapeutic utility such as targeting or efficacy. As discussed earlier, tags or other heterologous polypeptides can be appended to the sequence encoding the modified polypeptide, and "heterologous" means a polypeptide that is not the same as the modified polypeptide.

[0088] A. Hybridization Nucleic acids that hybridize to other nucleic acids under specific hybridization conditions. Methods for hybridizing nucleic acids are well known in the art. See, for example, Current Protocols in Molecular Biology, John Wiley and Sons, NY (1989), 6.3.1-6.3.6. Moderately stringent hybridization conditions, as defined herein, include a pre-washing solution containing 5× sodium chloride / sodium citrate (SSC), 0.5% SDS, and 1.0 mM EDTA (pH 8.0), a hybridization buffer of approximately 50% formamide and 6× SSC, and a hybridization temperature of 55°C (or other similar hybridization solutions, such as one with a hybridization temperature of 42°C and containing approximately 50% formamide), as well as washing conditions of 60°C in 0.5× SSC and 0.1% SDS. Under stringent hybridization conditions, hybridization is performed in 6×SSC at 45°C, followed by one or more washes in 0.1×SSC and 0.2% SDS at 68°C. Furthermore, those skilled in the art can manipulate the hybridization and / or washing conditions to increase or decrease the stringency of hybridization such that nucleic acids containing nucleotide sequences that are at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to one another, typically remain hybridized to one another.

[0089] Parameters influencing the selection of hybridization conditions and guidance for devising appropriate conditions are described, for example, by Sambrook, Fritsch, and Maniatis (both incorporated herein by reference in their entirety by all purposes: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11 (1989); Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley and Sons, Inc., sections 2.10 and 6.3-6.4 (1995)), and can be readily determined by those skilled in the art, for example, based on DNA length and / or base composition.

[0090] B. Mutation Mutation can introduce changes to nucleic acids, thereby altering the amino acid sequence of the polypeptide encoded by the nucleic acid (e.g., an antibody or antibody derivative). Mutations can be introduced using any technique known in the art. In one aspect, one or more specific amino acid residues may be modified, for example, using a site-directed mutagenesis protocol. In another aspect, one or more randomly selected residues may be modified, for example, using a random mutagenesis protocol. Regardless of how they are prepared, mutant polypeptides can be expressed and screened for desired properties.

[0091] Mutations can be introduced into nucleic acids without significantly altering the biological activity of the polypeptide encoded by the nucleic acid. For example, nucleotide substitutions can be made that result in amino acid substitutions at the position of non-essential amino acid residues. Alternatively, one or more mutations can be introduced into nucleic acids to selectively alter the biological activity of the encoding polypeptide. See, for example, Romain Studer et al., Biochem. J. 449:581-594 (2013). For example, mutations can alter biological activity quantitatively or qualitatively. Examples of quantitative changes include increased, decreased, or eliminated activity. An example of qualitative change is the alteration of the antigen specificity of an antibody.

[0092] C. Probe In another context, nucleic acid molecules are suitable for use as primers or hybridization probes for detecting nucleic acid sequences. Nucleic acid molecules may include only a portion of a nucleic acid sequence encoding a full-length polypeptide, for example, a fragment that can be used as a probe or primer, or only a fragment encoding the active portion of a given polypeptide.

[0093] In another context, nucleic acid molecules can be used as probes or PCR primers for specific antibody sequences. For example, nucleic acid molecule probes can be used in diagnostic methods, or, in particular, nucleic acid molecule PCR primers can be used to amplify regions of DNA that can be used to isolate nucleic acid sequences for use in the production of variable domains of antibodies. See, for example, Gaily Kivi et al., BMC Biotechnol. 16:2 (2016). In a preferred context, the nucleic acid molecule is an oligonucleotide. In a more preferred context, the oligonucleotide is derived from the heavy and light chains or alpha and beta chains of the antibody or TCR of interest. In an even more preferred context, the oligonucleotide encodes all or part of one or more CDRs or TCRs.

[0094] Using probes based on a desired nucleic acid sequence, nucleic acids or similar nucleic acids, such as transcripts encoding the polypeptide of interest, can be detected. The probes may include labeling groups, such as radioisotopes, fluorescent compounds, enzymes, or enzyme cofactors. Such probes can be used to identify cells expressing polypeptides.

[0095] IV. Polypeptide expression In some contexts, there are nucleic acid molecules (e.g., TCR genes) encoding polypeptides or peptides of the present disclosure. These can be produced by methods known in the art, for example, by isolating them from immunized and isolated mouse B cells, expressing them in phage display in any suitable recombinant expression system, and assembling them to form antibody molecules, or by recombinant methods.

[0096] A. Expression Nucleic acid molecules can be used to express large quantities of polypeptides. If the nucleic acid molecules are derived from non-human, non-transgenic animals, they can be used for the humanization of TCR genes.

[0097] B. Vector In some cases, expression vectors are intended to contain nucleic acid molecules encoding a polypeptide or a portion thereof of a desired sequence (e.g., a fragment containing one or more CDRs or one or more variable region domains). Nucleic acid molecule-containing expression vectors may encode heavy chains, light chains, alpha chains, beta chains, or their antigen-binding portions. In some cases, nucleic acid molecule-containing expression vectors may encode fusion proteins, modified antibodies, antibody fragments, and their probes. In addition to regulatory sequences that control transcription and translation, vectors and expression vectors may also contain nucleic acid sequences that perform other functions.

[0098] To express the polypeptide or peptide of this disclosure, DNA encoding the polypeptide or peptide is inserted into an expression vector such that the gene region is functionally linked to transcriptional and translational regulatory sequences. In some cases, a vector encoding a functionally complete human CH or CL immunoglobulin or TCR sequence having appropriate restriction sites engineered to allow for the easy insertion and expression of any variable region sequence. In some cases, a vector encoding a functionally complete human TCRα or TCRβ sequence having appropriate restriction sites engineered to allow for the easy insertion and expression of any variable sequence or CDR1, CDR2 and / or CDR3. Typically, an expression vector used in any of the host cells contains sequences for the maintenance of plasmids or viruses, as well as sequences for the cloning and expression of exogenous nucleotide sequences. Such sequences, collectively referred to as "flanking sequences," typically comprise one or more of the following functionally linked nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcription termination sequence, a complete intron sequence including donor and acceptor splice sites, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element. Such sequences and methods of using them are well known in the art.

[0099] C. Expression System Numerous expression systems exist that include at least some or all of the expression vectors described above. Prokaryotic and / or eukaryotic-based systems can be used in one aspect to produce nucleic acid sequences, or their homologous polypeptides, proteins, and peptides. Commercially and widely available systems include, but are not limited to, bacterial, mammalian, yeast, and insect cell systems. Different host cells have characteristic and specific mechanisms for post-translational processing and modification of proteins. Appropriate cell lines or host systems can be selected to ensure accurate modification and processing of expressed foreign proteins. Those skilled in the art can use appropriate expression systems to express vectors and produce nucleic acid sequences or their homologous polypeptides, proteins, or peptides.

[0100] V. Methods of gene transfer Suitable methods for nucleic acid delivery to bring about the expression of a composition are expected to include substantially any method by which nucleic acids (e.g., DNA, including viral and nonviral vectors) can be introduced into cells, tissues or organisms, as described herein or known to those skilled in the art. Such methods include injection (US Patents No. 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859, respectively, incorporated herein by reference), including microinjection (Harland and Weintraub, 1985; US Patent No. 5,789,215); by electroporation (US Patent No. 5,384,253, incorporated herein by reference); and by calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe et al., 1990). Transfection by: DEAE dextran followed by polyethylene glycol (Gopal, 1985); direct sonic loading (Fechheimer et al., 1987); liposome-mediated transfection (Nicolau and Sene, 1982; Fraley et al., 1979; Nicolau et al., 1987; Wong et al., 1980; Kaneda et al., 1989; Kato et al., 1991); and microprojectile impact (PCT application numbers WO 94 / 09699 and 95 / 06128). By means of stirring with silicon carbide fibers (Kaeppler et al., as incorporated herein by reference; Kaeppler et al., as incorporated herein by reference); by means of stirring with silicon carbide fibers (Kaeppler et al., as incorporated herein by reference).Methods include, but are not limited to, direct delivery of DNA, such as DNA uptake via drying / inhibition (Potrykus et al., 1985). Other methods include viral transduction, such as gene transfer by lentivirus or retroviral transduction.

[0101] A. host cell In another context, the use of host cells into which recombinant expression vectors have been introduced is intended. Antibodies can be expressed in various cell types. Expression constructs encoding antibodies can be transfected into cells by various methods known in the art. Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. Some vectors may utilize regulatory sequences that enable replication and / or expression in both prokaryotic and eukaryotic cells. In certain contexts, antibody expression constructs can be placed under the control of promoters associated with T cell activation, for example, those controlled by NFAT-1 or NF-κB, which are transcription factors that can both be activated upon T cell activation. Control of antibody expression enables T cells, such as tumor-targeting T cells, to sense their surroundings and carry out real-time regulation of cytokine signaling in both the T cells themselves and surrounding endogenous immune cells. Those skilled in the art will understand the conditions for incubating and maintaining host cells and enabling vector replication. Techniques and conditions that enable large-scale production of vectors, as well as the production of nucleic acids encoded by the vectors and their homologous polypeptides, proteins, or peptides, are also understood and known.

[0102] For stable transfection of mammalian cells, it is known that depending on the expression vector and transfection technique used, only a small fraction of cells can incorporate foreign DNA into their genome. To identify and select these incorporates, selectable markers (e.g., for antibiotic resistance) are generally introduced into host cells along with the gene of interest. Cells stably transfected with the introduced nucleic acid can be identified by drug selection, among other methods known in the art (e.g., cells incorporating the selectable marker gene survive while other cells die).

[0103] B. Isolation Nucleic acid molecules encoding the entirety or one or both of the heavy, light, alpha, and beta chains of an antibody or TCR, or their variable regions, can be obtained from any antibody-producing source. Methods for isolating antibody-encoding mRNA are well known in the art; see, for example, Sambrook et al., cited above. Sequences of human heavy and light chain constant region genes are also known in the art; see, for example, Kabat et al., 1991, cited above. Nucleic acid molecules encoding the full-length heavy and / or light chains can then be expressed in cells into which they have been introduced, and antibodies can be isolated.

[0104] VI. Further Treatment Options A. Immunotherapy In some aspects, this method involves administering further treatments. In some aspects, these further treatments include cancer immunotherapy. Cancer immunotherapy (sometimes called immuno-oncology, abbreviated as IO) is the use of the immune system to treat cancer. Immunotherapy can be classified as active, passive, or hybrid (active and passive). These approaches take advantage of the fact that cancer cells often have molecules on their surface that can be detected by the immune system, known as tumor-associated antigens (TAAs); these are often proteins or other macromolecules (e.g., carbohydrates). Active immunotherapy instructs the immune system to attack tumor cells by targeting TAAs. Passive immunotherapy enhances existing anti-tumor responses and includes the use of monoclonal antibodies, lymphocytes, and cytokines. Immunotherapy is well known in the art, and some are described below.

[0105] 1. Checkpoint inhibitors and concomitant treatments Aspects of this disclosure may include the administration of immune checkpoint inhibitors, which are further described below.

[0106] a. PD-1, PDL1, and PDL2 inhibitors PD-1 can act in the tumor microenvironment where T cells encounter infection or tumors. Activated T cells upregulate PD-1, and continue to express PD-1 in peripheral tissues. Cytokines such as IFN-gamma induce PDL1 expression in epithelial and tumor cells. PDL2 is expressed in macrophages and dendritic cells. The main role of PD-1 is to limit the activity of effector T cells in the periphery and prevent excessive tissue damage during the immune response. The inhibitors of this disclosure may block one or more functions of PD-1 and / or PDL1 activity.

[0107] Alternative names for "PD-1" include CD279 and SLEB2. Alternative names for "PDL1" include B7-H1, B7-4, CD274, and B7-H. Alternative names for "PDL2" include B7-DC, Btdc, and CD273. In some contexts, PD-1, PDL1, and PDL2 are human PD-1, PDL1, and PDL2.

[0108] In some contexts, a PD-1 inhibitor is a molecule that inhibits the binding of PD-1 to its ligand-binding partner. In certain contexts, the PD-1 ligand-binding partner is PDL1 and / or PDL2. In other contexts, a PDL1 inhibitor is a molecule that inhibits the binding of PDL1 to its ligand-binding partner. In certain contexts, the PDL1 binding partner is PD-1 and / or B7-1. In other contexts, a PDL2 inhibitor is a molecule that inhibits the binding of PDL2 to its ligand-binding partner. In certain contexts, the PDL2 binding partner is PD-1. The inhibitor may be an antibody, its antigen-binding fragment, an immunoadhesin, a fusion protein, or an oligopeptide. Exemplary antibodies are described in U.S. Patents 8,735,553, 8,354,509, and 8,008,449, all of which are incorporated herein by reference. Other PD-1 inhibitors for use in the methods and compositions provided herein are known in the art as described in U.S. Patent Publications US2014 / 0294898, US2014 / 022021, and US2011 / 0008369, all of which are incorporated herein by reference.

[0109] In some contexts, PD-1 inhibitors are anti-PD-1 antibodies (e.g., human antibodies, humanized antibodies, or chimeric antibodies). In some contexts, anti-PD-1 antibodies are selected from the group consisting of nivolumab, pembrolizumab, and pidilizumab. In some contexts, PD-1 inhibitors are immunoadhesins (e.g., immunoadhesins containing the extracellular portion or PD-1 binding moiety of PDL1 or PDL2 fused to a constant region (e.g., the Fc region of an immunoglobulin sequence)). In some contexts, PDL1 inhibitors include AMP-224. Nivolumab is also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558, and OPDIVO®, and is an anti-PD-1 antibody described in WO2006 / 121168. Pembrolizumab, also known as MK-3475, Merck3475, lambrolizumab, KEYTRUDA®, and SCH-900475, is an anti-PD-1 antibody described in WO2009 / 114335. Pidilizumab, also known as CT-011, hBAT, or hBAT-1, is an anti-PD-1 antibody described in WO2009 / 101611. AMP-224, also known as B7-DCIg, is a PDL2-Fc fusion soluble receptor described in WO2010 / 027827 and WO2011 / 066342. Further PD-1 inhibitors include MEDI0680, also known as AMP-514, and REGN2810.

[0110] In some contexts, immune checkpoint inhibitors are PDL1 inhibitors such as durvalumab (also known as MEDI4736), atezolizumab (also known as MPDL3280A), avelumab (also known as MSB00010118C), MDX-1105, BMS-936559, or combinations thereof. In certain contexts, immune checkpoint inhibitors are PDL2 inhibitors such as rHIgM12B7.

[0111] In some aspects, the inhibitor contains the heavy and light chain CDR or VR of nivolumab, pembrolizumab, or pidilizumab. Thus, in one aspect, the inhibitor contains the CDR1, CDR2, and CDR3 domains of the VH region of nivolumab, pembrolizumab, or pidilizumab, as well as the CDR1, CDR2, and CDR3 domains of the VL region of nivolumab, pembrolizumab, or pidilizumab. In another aspect, the antibody competes for binding to the same epitopes on PD-1, PDL1, or PDL2 as the aforementioned antibody, and / or binds to the same epitopes on PD-1, PDL1, or PDL2 as the aforementioned antibody. In yet another aspect, the antibody has at least about 70, 75, 80, 85, 90, 95, 97, or 99% (or within a derivable range) of variable region amino acid sequence identity with respect to the aforementioned antibody.

[0112] b. CTLA-4, B7-1, and B7-2 Another immune checkpoint that may be targeted in the methods provided herein is cytotoxic T lymphocyte protein 4 (CTLA-4), also known as CD152. The complete cDNA sequence of human CTLA-4 has Genbank accession number L15006. CTLA-4 is found on the surface of T cells and acts as an "off" switch when it binds to B7-1 (CD80) or B7-2 (CD86) on the surface of antigen-presenting cells. CTLA4 is a member of the immunoglobulin superfamily that is expressed on the surface of helper T cells and transmits inhibitory signals to T cells. CTLA4 is analogous to the T cell co-stimulatory protein CD28, and both molecules bind to B7-1 and B7-2 on antigen-presenting cells. CTLA-4 transmits inhibitory signals to T cells, while CD28 transmits stimulating signals. Intracellular CTLA-4 is also found in regulatory T cells and may be important for their function. When T cells are activated via the T cell receptor and CD28, the expression of CTLA-4, an inhibitory receptor for the B7 molecule, increases. The inhibitors of this disclosure may block one or more functions of CTLA-4, B7-1, and / or B7-2 activity. In some aspects, the inhibitors block the CTLA-4 and B7-1 interaction. In some aspects, the inhibitors block the CTLA-4 and B7-2 interaction.

[0113] In some aspects, immune checkpoint inhibitors are anti-CTLA-4 antibodies (e.g., human antibodies, humanized antibodies, or chimeric antibodies), their antigen-binding fragments, immunoadhesins, fusion proteins, or oligopeptides.

[0114] Anti-human CTLA-4 antibodies (or VH and / or VL domains derived therefrom) suitable for use in the method of the present invention can be prepared using methods well known in the art. Alternatively, anti-CTLA-4 antibodies recognized in the art can be used. For example, the anti-CTLA-4 antibodies disclosed in U.S. Patent No. 8,119,129, WO01 / 14424, WO98 / 42752; WO00 / 37504 (CP675,206, tremelimumab; formerly also known as ticilimumab), U.S. Patent No. 6,207,156; Hurwitz et al., 1998 can be used in the method disclosed herein. The disclosures of each of the aforementioned publications are incorporated herein by reference. Antibodies that compete with any of these art-recognized antibodies for binding to CTLA-4 can also be used. For example, humanized CTLA-4 antibodies are described in International Patent Application Nos. WO2001 / 014424, WO2000 / 037504, and U.S. Patent No. 8,017,114, all of which are incorporated herein by reference.

[0115] Further anti-CTLA-4 antibodies useful as checkpoint inhibitors in the methods and compositions of this disclosure are ipilimumab (also known as 10D1, MDX-010, MDX-101, and Yervoy®) or its antigen-binding fragments and variants (see, for example, WO01 / 14424).

[0116] In some aspects, the inhibitor contains the heavy and light chain CDR or VR of tremelimumab or ipilimumab. Thus, in one aspect, the inhibitor contains the CDR1, CDR2, and CDR3 domains of the VH region of tremelimumab or ipilimumab, as well as the CDR1, CDR2, and CDR3 domains of the VL region of tremelimumab or ipilimumab. In another aspect, the antibody competes for binding to the same epitopes on PD-1, B7-1, or B7-2 as the aforementioned antibody, and / or binds to the same epitopes on PD-1, B7-1, or B7-2 as the aforementioned antibody. In yet another aspect, the antibody has at least about 70, 75, 80, 85, 90, 95, 97, or 99% (or within the derivable range) of variable region amino acid sequence identity with respect to the aforementioned antibody.

[0117] 2. Inhibition of co-stimulatory molecules In some aspects, immunotherapy involves inhibitors of co-stimulatory molecules. In some aspects, inhibitors include inhibitors of B7-1 (CD80), B7-2 (CD86), CD28, ICOS, OX40 (TNFRSF4), 4-1BB (CD137; TNFRSF9), CD40L (CD40LG), GITR (TNFRSF18), and combinations thereof. Inhibitors include inhibitory antibodies, polypeptides, compounds, and nucleic acids.

[0118] 3. Dendritic cell therapy Dendritic cell therapy induces an antitumor response by having dendritic cells present tumor antigens to lymphocytes, thereby activating the lymphocytes and stimulating them to kill other cells that are presenting the antigens. Dendritic cells are antigen-presenting cells (APCs) in the mammalian immune system. In cancer treatment, dendritic cells help target cancer antigens. One example of dendritic cell-based cell carcinoma therapy is cyplücel-T.

[0119] One method to induce dendritic cells to present tumor antigens is by vaccinating them with autologous tumor lysates or short peptides (small portions of proteins corresponding to protein antigens on cancer cells). These peptides are often given in combination with adjuvants (highly immunogenic substances) to enhance the immune and antitumor response. Other adjuvants include proteins or other chemicals that attract and / or activate dendritic cells, such as granulocyte-macrophage colony-stimulating factor (GM-CSF).

[0120] Dendritic cells can also be activated in vivo by inducing GM-CSF expression in tumor cells. This can be achieved by genetically engineering tumor cells to produce GM-CSF, or by infecting tumor cells with an oncolytic virus that expresses GM-CSF.

[0121] Another strategy involves extracting dendritic cells from the patient's blood and activating them in vitro. The dendritic cells are activated in the presence of a tumor antigen, which can be a single tumor-specific peptide / protein or tumor cell lysate (a solution of destroyed tumor cells). These cells (with a selective adjuvant) are then injected to trigger an immune response.

[0122] Dendritic cell therapy involves the use of antibodies that bind to receptors on the surface of dendritic cells. Antigens can be added to the antibodies, inducing dendritic cells to mature and providing immunity against tumors. Dendritic cell receptors such as TLR3, TLR7, TLR8, or CD40 are used as antibody targets.

[0123] 4. CAR-T cell therapy Chimeric antigen receptors (also known as chimeric immune receptors, chimeric T cell receptors, or artificial T cell receptors, CARs) are engineered receptors that combine immune cells with novel specificity to target cancer cells. Typically, these receptors transfer the specificity of monoclonal antibodies to T cells. The receptors are called chimeric because parts from different sources are fused together. CAR-T cell therapy refers to treatments that use such transformed cells for cancer treatment.

[0124] The fundamental principle of CAR-T cell design involves recombinant receptors that combine antigen-binding and T-cell activation functions. The general premise of CAR-T cells is the artificial creation of T cells that target markers found on cancer cells. Scientists can extract T cells from a person, genetically modify them, and then return them to the patient to attack cancer cells. Once a T cell is engineered to become a CAR-T cell, it acts as a "living drug." CAR-T cells create a link between an extracellular ligand-recognition domain and an intracellular signaling molecule, which activates the T cell. The extracellular ligand-recognition domain is typically a single-stranded variable fragment (scFv). A critical aspect of the safety of CAR-T cell therapy is ensuring that only cancerous tumor cells, and not normal cells, are targeted. The specificity of CAR-T cells is determined by the selection of the target molecule.

[0125] Exemplary CAR-T therapies include tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). In some aspects, CAR-T therapies target CD19.

[0126] 5. Cytokine therapy Cytokines are proteins produced by many types of cells present within tumors. They can modulate the immune response. Tumors often utilize cytokines to promote tumor growth and reduce the immune response. These immunomodulatory effects make it possible to use them as drugs to induce an immune response. Two commonly used cytokines are interferons and interleukins.

[0127] Interferons are produced by the immune system. They are typically involved in antiviral responses, but are also used in cancer treatment. They are classified into three groups: Type I (IFNα and IFNβ), Type II (IFNγ), and Type III (IFNλ).

[0128] Interleukins possess numerous immune system effects. IL-2 is an exemplary interleukin cytokine therapy.

[0129] 6. Adoptive T cell therapy Adoptive T-cell therapy is a form of passive immunity through T-cell transfusion (adoptive cell transfer). T cells are found in blood and tissues and are normally activated when they encounter foreign pathogens. Specifically, T cells are activated when their surface receptors encounter cells that present a portion of a foreign protein on a surface antigen. These can be either infected cells or antigen-presenting cells (APCs). They are found in normal tissues and tumor tissues, in which case they are known as tumor-infiltrating lymphocytes (TILs). They are activated by the presence of APCs such as dendritic cells that present tumor antigens. These cells can attack tumors, but the intratumor environment is highly immunosuppressive, preventing immune-mediated tumor death.

[0130] Several methods have been developed to produce and obtain tumor-targeted T cells. Tumor antigen-specific T cells can be isolated from tumor samples (TILs) or filtered from blood. Subsequent activation and culture are performed ex vivo, and the cells are then reinjected. Activation can be achieved through gene therapy or by exposing T cells to tumor antigens.

[0131] B. Chemotherapy In some cases, further treatment involves chemotherapy. Suitable classes of chemotherapeutic agents include: (a) alkylating agents, e.g., nitrogen mustards (e.g., mechloretamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimines and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, chlorozotocin, streptozocin) and triazines (e.g., dicarbazine); (b) antimetabolites, e.g., folate analogs (e.g., methotrexate), pyrimidine analogs (e.g., 5-fluorouracil, phloxuridine, cytarabine, azauridine) and purine analogs and related substances (e.g., 6-mercaptopurine, 6-thioguanine, pentostatin); (c) The present invention includes natural products, such as vinca alkaloids (e.g., vinblastine, vincristine), epipodophyllotoxins (e.g., etoposide, teniposide), antibiotics (e.g., dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, and mitoxantrone), enzymes (e.g., L-asparaginase), and biological response modifiers (e.g., interferon-α), as well as (d) various active agents, such as platinum-coordinate complexes (e.g., cisplatin, carboplatin), substituted ureas (e.g., hydroxyurea), methylhydrazine derivatives (e.g., procarbazine), and adrenal cortical inhibitors (e.g., taxol and mitotane). In some aspects, cisplatin is a particularly suitable chemotherapeutic agent.

[0132] Cisplatin has been widely used to treat cancers such as metastatic testicular or ovarian cancer, advanced bladder cancer, head and neck cancer, cervical cancer, lung cancer, or other tumors. Cisplatin is not absorbed orally and therefore must be delivered via other routes, such as intravenous, subcutaneous, intratumoral, or intraperitoneal injection. Cisplatin can be used alone or in combination with other agents, and effective doses used in clinical applications are intended, including approximately 15 mg / m2 to approximately 20 mg / m2 over 5 days every 3 weeks for a total of 3 processes in certain situations. In some situations, the amount of cisplatin delivered to cells and / or subjects in combination with a construct containing an Egr-1 promoter functionally linked to a polynucleotide encoding a therapeutic polypeptide is less than the amount that would be delivered if cisplatin were used alone.

[0133] Other suitable chemotherapeutic agents include antimicrotubule agents, such as paclitaxel ("Taxol") and doxorubicin hydrochloride ("Doxorubicin"). The combination of the Egr-1 promoter / TNFα construct delivered via an adenovirus vector and doxorubicin has been shown to be effective in overcoming resistance to chemotherapy and / or TNF-α, suggesting that combination treatment with the construct and doxorubicin overcomes resistance to both doxorubicin and TNF-α.

[0134] Doxorubicin is poorly absorbed and is preferably administered intravenously. In certain situations, an appropriate intravenous dose for adults includes approximately 60 mg / m2 to 75 mg / m2 at approximately 21-day intervals, or approximately 25 mg / m2 to 30 mg / m2 on each of two or three consecutive days, repeated at approximately 3 to 4-week intervals, or approximately 20 mg / m2 once a week. The lowest dose should be used in elderly patients if there is prior myelosuppression or neoplastic myeloinfiltration caused by previous chemotherapy, or if the drug is combined with other myelopoiopioid suppressants.

[0135] Nitrogen mustard is another suitable chemotherapeutic agent useful in the methods of the present disclosure. Nitrogen mustard may include, but is not limited to, mechloretamine (HN2), cyclophosphamide and / or ifosfamide, melphalan (L-sarcolicin), and chlorambucil. Cyclophosphamide (CYTOXAN® is available from Mead Johnson, and NEOSTAR® is available from Adria) is another suitable chemotherapeutic agent. Suitable oral doses for adults include, for example, about 1 mg / kg / day to about 5 mg / kg / day, and intravenous doses include, for example, initially in divided doses of about 40 mg / kg to about 50 mg / kg over about 2 to about 5 days, or about 10 mg / kg to about 15 mg / kg every 7 to about 10 days, or twice weekly, about 3 mg / kg to about 5 mg / kg, or about 1.5 mg / kg to about 3 mg / kg / day. Due to potential adverse effects on the gastrointestinal tract, intravenous administration is preferred. Drugs may also be administered intramuscularly, by infiltration, or into body cavities.

[0136] Further suitable chemotherapeutic agents include pyrimidine analogs such as cytarabine (cytosine arabinoside), 5-fluorouracil (fluorouracil; 5-FU), and floxuridine (fluorodeoxyuridine; FudR). 5-FU can generally be administered to subjects at doses ranging from about 7.5 to about 1000 mg / m2. Furthermore, the 5-FU dosing schedule may vary in duration, for example, up to 6 weeks, or may be determined by those skilled in the art to whom this disclosure relates.

[0137] Another suitable chemotherapeutic agent, gemcitabine diphosphate (GEMZAR®, Eli Lilly & Co., "gemcitabine"), is recommended for the treatment of advanced and metastatic pancreatic cancer and therefore would also be useful in this disclosure for these cancers.

[0138] The amount of chemotherapeutic agent delivered to a patient may be variable. In one appropriate context, the chemotherapeutic agent may be administered in an amount effective to cause cancer cessation or regression in the host when the chemotherapy is administered with a construct. In other contexts, the chemotherapeutic agent may be administered in amounts generally 2 to 10,000 times less than the chemotherapeutic effective dose of the chemotherapeutic agent. For example, the chemotherapeutic agent may be administered in amounts approximately 20 times, 500 times, or even 5,000 times less than the chemotherapeutic effective dose of the chemotherapeutic agent. The chemotherapeutic agents of this disclosure can be tested in vivo for the desired therapeutic activity in combination with a construct and for determining an effective dose. For example, such compounds can be tested in appropriate animal model systems, including but not limited to rats, mice, chickens, cattle, monkeys, and rabbits, before testing in humans. As described in the examples, in vitro testing can also be used to determine appropriate combinations and doses.

[0139] C. Radiation therapy In some cases, further or previous treatments involve radiation, such as ionizing radiation. As used herein, “ionizing radiation” means radiation that has sufficient energy or that contains particles or photons capable of generating sufficient energy through nuclear interactions to produce ionization (gain or loss of electrons). An exemplary and preferred ionizing radiation is X-rays. Means for delivering X-rays to target tissue or cells are well known in the art.

[0140] D. Surgery In some cases, further treatment involves surgery. Approximately 60% of people with cancer undergo some form of surgery, including prophylactic surgery, surgery for diagnosis or staging, radical surgery, and palliative surgery. Radical surgery involves excision in which all or part of the cancerous tissue is physically removed, excised, and / or destroyed, and may be used in conjunction with other therapies such as treatment of the aspects of the present invention, chemotherapy, radiotherapy, hormone therapy, gene therapy, immunotherapy, and / or alternative therapies. Tumor excision means the physical removal of at least a portion of the tumor. In addition to tumor excision, surgical treatments include laser surgery, cryosurgery, electrosurgery, and microscopically-controlled surgery (Mohs procedure).

[0141] When cancer cells, tissue, or part or all of a tumor are removed, a cavity may form in the body. Treatment may be carried out by perfusing, directly injecting, or topically applying further anticancer therapies to the area. Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks, or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months (or any range within which it can be derived). These treatments may also be administered in varying doses.

[0142] VII. Detection and Therapeutic Agents In some aspects of this disclosure, it would be useful to detectably or therapeutically label the TCR or fusion protein of this disclosure. Methods for conjugating polypeptides with these agents are known in the art. For illustrative purposes only, polypeptides can be labeled with detectable moieties such as radioactive atoms, chromophores, fluorophores, etc. Such labeled polypeptides can be used in diagnostic techniques in vivo, in isolated test samples, or in the manner described herein.

[0143] As used herein, the term “labeled” refers to a directly or indirectly detectable compound or composition that, when directly or indirectly conjugated with a composition to be detected, such as a polynucleotide or a protein such as an antibody, results in a “labeled” composition. The term also includes sequences conjugated with polynucleotides, such as green fluorescent protein (GFP), which produce a signal when the inserted sequence is expressed. Labels may be detectable in themselves (e.g., radioisotope labeling or fluorescent labeling), or, in the case of enzymatic labeling, may catalyze a chemical change in a detectable substrate compound or composition. Labels may be suitable for small-scale detection or for high-throughput screening. Therefore, suitable labels include, but are not limited to, radioisotopes, fluorescent dyes, chemiluminescent compounds, dyes, and proteins, including enzymes. Labels may be simply detected or quantified. A simply detected response generally includes a response that simply confirms its presence, while a quantified response generally includes a response with quantifiable (e.g., numerically reportable) values ​​such as intensity, polarization, and / or other properties. In luminescence or fluorescence assays, a detectable response may occur directly using a luminescent phore or fluorophore associated with the assay component actually involved in binding, or indirectly using a luminescent phore or fluorophore associated with another component (e.g., a reporter or indicator).

[0144] Examples of luminescent labels that produce signals include, but are not limited to, bioluminescence and chemiluminescence. Detectable luminescence responses generally involve changes in or the generation of a luminescent signal. Suitable methods and luminescent phores for luminescently labeling assay components are known in the art, for example, Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6 thThis is described in (ed.). Examples of luminescent probes include, but are not limited to, aequorin and luciferase.

[0145] Suitable fluorescent labels include, but are not limited to, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methylcoumarin, pyrene, malasite green, stilbene, Lucifer yellow, Cascade Blue (trademark), and Texas red. Other suitable optical dyes are listed in Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6 th It is described in the ed.

[0146] In another context, fluorescent labels are functionalized to facilitate covalent bonding with cellular components present in or on the surface of cells or tissues, such as cell surface markers. Suitable functional groups include, but are not limited to, isothiocyanate groups, amino groups, haloacetyl groups, maleimide, succinimidyl esters, and sulfonyl halides, all of which can be used to bond the fluorescent label to a second molecule. The selection of the functional group of the fluorescent label will depend on the binding site with the linker, agent, marker, or second labeling agent.

[0147] The fluorescent label may be bound directly to the cellular component or compound, or alternatively, via a linker. Suitable binding pairs for indirectly linking the fluorescent label to the intermediate include, but are not limited to, antigen / polypeptide pairs such as rhodamine / anti-rhodamine, biotin / avidin, and biotin / streptavidin.

[0148] Coupling polypeptides with low molecular weight haptens can increase the sensitivity of antibodies in assays. Subsequently, a second reaction allows for specific detection of the hapten. For example, haptens such as biotin, which reacts with avidin, or dinitrophenol, pyridoxal, and fluorescein, which can react with specific anti-hapten polypeptides, are commonly used. See Harlow and Lane (1988), mentioned above.

[0149] The conjugated agent can be linked to the polypeptide directly or indirectly using one of several available methods. For example, the agent can be linked to the hinge region of the reduced antibody component via disulfide bond formation using a crosslinking agent such as N-succinyl 3-(2-pyridyldithio)propionate (SPDP), or via the carbohydrate moiety in the Fc region of the antibody (Yu et al., 1994; Upeslacis et al., 1995; Price, 1995).

[0150] Techniques for conjugating agents into polypeptides are well known (Amon et al., 1985; Hellstrom et al., 1987; Thorpe, 1985; Baldwin et al., 1985; Thorpe et al., 1982).

[0151] The polypeptides of this disclosure or their antigen-binding domains can be linked to other functional molecules, such as ligands, cytotoxic molecules, chemotherapeutic agents, or other agents described as further therapeutic substances.

[0152] VIII. Cell formulation and culture In certain contexts, the cells of this disclosure may be formulated in particular, and / or they may be cultured in specific media. The cells may be formulated in a manner suitable for delivery to recipients without adverse effects.

[0153] In certain situations, culture media may be prepared using as a basal medium any of the media used to culture animal cells, such as AIM V, X-VIVO-15, NeuroBasal, EGM2, TeSR, BME, BGJb, CMRL 1066, Glasgow MEM, Modified MEM Zinc Option, IMDM, 199 medium, Eagle MEM, αMEM, DMEM, Ham, RPMI-1640, and Fischer medium, or any combination thereof, but the media are not particularly limited to those, as long as they can be used to culture animal cells. In particular, the media may be xeno-free or chemically defined.

[0154] The culture medium may be serum-containing, serum-free, or xeno-free. To prevent contamination by components from other animal species, the serum may be derived from the same animal as the stem cells. Serum-free media are those that do not contain unprocessed or unpurified serum, and therefore may contain purified blood-derived components or animal tissue-derived components (such as growth factors).

[0155] The culture medium may or may not contain any serum substitute. Serum substitutes may include materials appropriately containing albumin (such as lipid-rich albumin, bovine albumin, recombinant albumin or humanized albumin, vegetable starch, dextran, and protein hydrolysates), transferrin (or other iron transporters), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thioglycerol, or equivalents thereof. Serum substitutes may be prepared by the method disclosed, for example, in International Publication No. 98 / 30679 (which is incorporated herein in its entirety). Alternatively, for greater convenience, any commercially available material may be used. Commercially available materials include knockout serum replacement (KSR), chemically-defined lipid concentrated (Gibco), and Glutamax (Gibco).

[0156] In certain contexts, the culture medium may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more types of other components such as biotin; DL-alpha-tocopherol acetate; DL-alpha-tocopherol; vitamins such as vitamin A (acetate); BSA (bovine serum albumin) or human albumin, fatty acid-free fraction V; catalase; human recombinant insulin; human transferrin; proteins such as superoxide dismutase; corticosterone; D-galactose; ethanolamine HCl; glutathione (reduced); L-carnitine HCl; linoleic acid; linolenic acid; progesterone; putrescine 2HCl; sodium selenite; and / or T3 (triiodo-I-thyronine). In certain situations, one or more of these may be explicitly excluded.

[0157] In some aspects, the culture medium further contains vitamins. In some aspects, the culture medium contains one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen of the following (and any range derivable therefrom): biotin, DL-alpha-tocopherol acetate, DL-alpha-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid nicotinamide, pyridoxine, riboflavin, thiamine, inositol, and vitamin B12 (and any range derivable therefrom), or the culture medium contains a combination thereof or salts thereof. In some aspects, the culture medium contains or essentially consists of biotin, DL-alpha-tocopherol acetate, DL-alpha-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid nicotinamide, pyridoxine, riboflavin, thiamine, inositol, and vitamin B12. In some aspects, the vitamins include or are essentially composed of biotin, DL-alpha-tocopherol acetate, DL-alpha-tocopherol, vitamin A, or a combination or salt thereof. In some aspects, the medium further includes proteins. In some aspects, the proteins include albumin or bovine serum albumin, a fraction of BSA, catalase, insulin, transferrin, superoxide dismutase, or a combination thereof. In some aspects, the medium further includes one or more of corticosterone, D-galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, or triiodo-I-thyronine, or a combination thereof. In some aspects, the medium includes one or more of B-27® supplements, Xenofree B-27® supplements, GS21® supplements, or a combination thereof. In some aspects, the culture medium contains, or further contains, amino acids, monosaccharides, and inorganic ions.In some aspects, amino acids include arginine, cystine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine, or combinations thereof. In some aspects, inorganic ions include sodium, potassium, calcium, magnesium, nitrogen, or phosphorus, or combinations thereof or salts thereof. In some aspects, the culture medium further includes one or more of molybdenum, vanadium, iron, zinc, selenium, copper, or manganese, or combinations thereof. In certain contexts, the culture medium may contain or be essentially composed of one or more of the following: one or more of the vitamins discussed herein, and / or one or more of the proteins discussed herein, and / or the following: corticosterone, D-galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, or triiodo-I-thyronine, B-27® supplement, Xenofree B-27® supplement, GS21® supplement, amino acids (such as arginine, cystine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine), monosaccharides, inorganic ions (such as sodium, potassium, calcium, magnesium, nitrogen, and / or phosphorus) or salts thereof, and / or one or more of the following: molybdenum, vanadium, iron, zinc, selenium, copper, or manganese. In certain situations, one or more of these may be explicitly excluded.

[0158] The culture medium may also contain one or more externally added fatty acids or lipids, amino acids (such as non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, pyruvate, buffers, and / or inorganic salts. In certain circumstances, one or more of these may be explicitly excluded.

[0159] One or more of the culture medium components are at least 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 180, 200, 250 ng / L, ng / ml, μg / ml, mg / ml or any range derivable within that range, and at most 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 180, 200, 250 It may be added at concentrations of ng / L, ng / ml, μg / ml, mg / ml or any range within which it can be derived, or approximately 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 180, 200, 250 ng / L, ng / ml, μg / ml, mg / ml or any range within which it can be derived.

[0160] In certain contexts, the cells of this disclosure are formulated in particular. They may or may not be formulated as cell suspensions. In certain cases, they are formulated in single-dose form. They may be formulated for systemic or topical administration. In some cases, the cells are formulated for storage before use, and the cell formulation may contain one or more cryopreserving agents, such as DMSO (e.g., in 5% DMSO). The cell formulation may contain albumin, including human albumin, and certain formulations contain 2.5% human albumin. The cells may be formulated in particular for intravenous administration; for example, they are formulated for intravenous administration over a period of less than one hour. In certain contexts, the cells are in a formulated cell suspension that is stable at room temperature for one, two, three or four hours or longer from thawing.

[0161] In certain contexts, the cells of this disclosure may contain an exogenous TCR, which may be of defined antigen specificity. In some contexts, the TCR may be selected based on the absence or reduction of alloreactivity to the intended recipient (e.g., a specific virus-specific TCR, a heterologous-specific TCR, or a cancer-testis antigen-specific TCR). In cases where the exogenous TCR is non-allologous, during T cell differentiation, the exogenous TCR represses the rearrangement and / or expression of the endogenous TCR locus through a developmental process called allele exclusion, resulting in T cells that express only the non-allologous exogenous TCR and are therefore non-allologous. In some contexts, the selection of the exogenous TCR may not necessarily be based on the absence of alloreactivity. In some contexts, the endogenous TCR gene has been modified by genome editing to not express the protein. Methods of gene editing, such as those using the CRISPR / Cas9 system, are known in the art and are described herein.

[0162] In some aspects, the cells of this disclosure further comprise one or more chimeric antigen receptors (CARs). Examples of tumor cell antigens to which CARs may be directed include, for example, at least 5T4, 8H9, αvβ6 integrin, BCMA, B7-H3, B7-H6, CAIX, CA9, CD19, CD20, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7 / 8, CD70, CD123, CD138, CD171, CEA, CSPG4, EGFR, ErbB2 (HER2), EGFR family including EGFRvIII, EGP2, EGP40, ERBB3, ERBB4, ErbB3 / 4, EPCAM, EphA2, EpCAM, folate receptor-a, FAP, FBP, fetal AchR, FRα, GD2, G250 / CAIX, GD3, and glypican-3. (GPC3), Her2, IL-13Rα2, Lambda, Lewis-Y, Kappa, KDR, MAGE, MCSP, Mesothelin, Muc1, Muc16, NCAM, NKG2D ligand, NY-ESO-1, PRAME, PSC1, PSCA, PSMA, ROR1, SP17, Survivin, TAG72, TEM, Carcinoembryonic antigen, HMW-MAA, AFP, CA-125, ETA, Tyrosinase, MAGE, Laminin receptor, HPV Examples include E6, E7, BING-4, calcium-activated chloride channel 2, cyclin-B1, 9D7, EphA3, telomerase, SAP-1, BAGE family, CAGE family, GAGE ​​family, MAGE family, SAGE family, XAGE family, NY-ESO-1 / LAGE-1, PAME, SSX-2, melan-A / MART-1, GP100 / pmel17, TRP-1 / -2, P. polypeptide, MC1R, prostate-specific antigen, β-catenin, BRCA1 / 2, CML66, fibronectin, MART-2, TGF-βRII, or VEGF receptor (e.g., VEGFR2). The CAR may be a first-generation, second-generation, third-generation, or higher-generation CAR. The CAR may be bispecific to any two non-identical antigens, or specific to three or more non-identical antigens.

[0163] IX. Administration of therapeutic composition The therapies provided herein may include the administration of a combination of therapeutic agents, such as a first cancer therapy and a second cancer therapy. The therapies may be administered in any suitable method known in the art. For example, the first and second cancer treatments may be administered sequentially (at different times) or simultaneously (at the same time). In some aspects, the first and second cancer treatments may be administered in separate compositions. In some aspects, the first and second cancer treatments may be in the same composition.

[0164] This disclosure relates to compositions and methods, including therapeutic compositions. Different therapeutic methods may be administered in one composition, or in two or more compositions, such as two, three, or four compositions. Various combinations of agents may be used.

[0165] The therapeutic compositions disclosed herein may be administered by the same or different routes of administration. In some cases, cancer treatments are administered intravenously, intramuscularly, subcutaneously, topically, orally, percutaneously, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. In some cases, antibiotics are administered intravenously, intramuscularly, subcutaneously, topically, orally, percutaneously, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. The appropriate dosage may be determined based on the type of disease being treated, the severity and course of the disease, the individual's clinical condition, the individual's medical history and response to treatment, and the discretion of the attending physician.

[0166] Treatment may involve various "unit doses." A unit dose is defined as containing a predetermined amount of the therapeutic composition. The amount administered, as well as the specific route and formulation, is within the scope of the skills of those skilled in the art in the clinical field. A unit dose does not necessarily have to be administered as a single injection, but may include a continuous infusion over a set period of time. In some contexts, a unit dose may include a single administerable dose.

[0167] The appropriate amount of therapeutic composition also depends on the practitioner's judgment and is specific to each individual. Factors influencing the dosage include the patient's physical and clinical condition, route of administration, intended treatment goal (symptom relief vs. cure), and the potency, stability, and toxicity of any specific therapeutic substance or other treatment the subject may be receiving.

[0168] X. Kit A particular aspect of the present invention also relates to a kit comprising a composition of the present disclosure or a composition for carrying out a method of the present invention. In some aspects, the kit can be used to evaluate one or more biomarkers or HLA types. In some aspects, the kit can evaluate 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 100, 500, 1,000 or more pros. Includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 4 0, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 100, 500, 1,000 or more probes, primers or primer sets, synthetic molecules or inhibitors, or any values ​​or ranges and combinations deriveable therefrom, or at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 , including 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 100, 500, 1,000 or more probes, primers or primer sets, synthetic molecules or inhibitors, or any values ​​or ranges and combinations thereof that can be derived.

[0169] The kit may include components that can be individually packaged or arranged in containers such as tubes, bottles, vials, syringes, or other suitable container means.

[0170] Individual components may be provided in concentrated quantities within the kit; in some cases, components are provided individually at the same concentrations as they would be in a solution containing the other components. Component concentrations may be 1x, 2x, 5x, 10x, 20x, or higher.

[0171] In certain aspects, negative and / or positive control nucleic acids, probes, and inhibitors are included in some kit aspects. Furthermore, the kit may include samples that are negative or positive controls for the methylation of one or more biomarkers.

[0172] It is intended that any method or composition described herein can be implemented in relation to any other method or composition described herein, and that different aspects can be combined. The initial claims are intended to cover claims that depend in combination with any or any combination of the claims filed herein. [Examples]

[0173] XI. Examples The following embodiments are included to demonstrate preferred embodiments of the Disclosure. Those skilled in the art will recognize that the methods disclosed in the following embodiments are methods that the inventors have found to function well in the implementation of the Disclosure, and therefore may be considered to constitute preferred embodiments for implementation. However, those skilled in the art will recognize that, in view of the Disclosure, many modifications can be made in the specific embodiments disclosed without departing from the spirit and scope of the Disclosure, but similar or comparable results can still be obtained.

[0174] Example 1: Design and testing of EGFR-specific T cell receptors HLA-A*3101-transduced H1975 cells were pulsed with EGFR (L858R) peptide (HVKITDFGR - SEQ ID NO:85) and co-cultured for 4 hours with selected TCR-transduced T cells at the indicated E:T ratio. T cell-killing activity was determined by measuring Cr51 release in the supernatant. TCR-mediated cytotoxicity of clones 1 and 2 is shown in Figure 1. H1975-A*3101 or HLA-A*3303-transduced 293 target cells were pulsed with different amounts of HVKITDFGR (SEQ ID NO:85) peptide. 1 × 10⁻⁶ 5Target cells and TCR transduction effector cells were seeded in each well and incubated overnight. The number of spots in Figure 3 represents the number of IFN-gamma secreting T cells that responded to peptide recognition of the peptide mutant EGFR. TCR-expressing viruses were transduced into PBMCs, and TCR transduction tetramer-positive T cells were selected. Next, 293 HLA*A33:03 cells were pulsed with the HVKITDFGR (SEQ ID NO:85) peptide and labeled with Cr51. Figures 4-5 show the specific lysis of target cells incubated with effectors (EGFR TCR-specific T cells) for 4 hours at different E:T ratios. Cr51 release was measured. 293 cells stably expressing HLA-A*3301 and wild-type (WT) or L858R mutant EGFR genes were co-cultured with selected TCR-T cells expressing TCR33-32H in various ratios. After a 4-hour incubation, released Cr51 activity was measured (Figure 6). As shown in Figure 6, TCR33-32H can recognize and kill 293 cells transduced to express the entire EGFR-L858R gene. This experiment demonstrates the innate processing and presentation of the HVKITDFGR (SEQ ID NO:85) neoantigen peptide by tumor cells. Comparison of killing activity of different EGFR-A33 TCR clones. Three different EGFR-A33 TCRs (TCR32H, TCR37-3, and TCR33-4) were transduced into normal PBMCs. Tetrameric and CD8 double-positive T cells were co-cultured with 293 cells stably expressing WT or L858R mutant EGFR genes. Killing activity at various E:T ratios was compared by a Cr51 release assay (Figure 7). These experiments collectively demonstrate that cloned and expressed EGFR neoantigen-specific TCRs can recognize HLA-A*3301 or A*3303-expressing tumor target cells pulsed with the congeneral peptide antigen HVKITDFGR (SEQ ID NO:85) or cells transduced to express full-length EGFR (L858R) protein instead of wild-type EGFR, conferring to T cells the ability to secrete interferon-gamma and kill these cells.Figure 7 demonstrates that the neoantigen peptide HVKITDFGR (SEQ ID NO:85) can be spontaneously processed from full-length mutant EGFR protein and presented on HLA-A*3101 and A*3303.

[0175] All methods disclosed and asserted herein can be prepared and carried out without excessive experimentation in consideration of the present invention. While the compositions and methods of the present invention have been described in preferred embodiments, it will be apparent to those skilled in the art that the methods and the steps or order of steps described herein can be modified without departing from the concept, spirit, and scope of the present invention. More specifically, it will be apparent that certain chemically and physiologically related agents can be used instead of the agents described herein, and that the same or similar results can be obtained at the same time. All such similar substitutions and modifications, which will be apparent to those skilled in the art, are considered to be within the spirit, scope, and concept of the present invention as defined by the appended claims.

Claims

1. A polypeptide comprising an antigen-binding variable region comprising a CDR3, (a) comprises an amino acid sequence of SEQ ID NO:22 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:22; (b) comprises an amino acid sequence of SEQ ID NO:28 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:28; (c) comprising an amino acid sequence of SEQ ID NO:8 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:8; (d) comprising an amino acid sequence of SEQ ID NO:14 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:14; (e) comprising an amino acid sequence of SEQ ID NO:36 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:36; (f) comprising an amino acid sequence of SEQ ID NO:42 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:42; (g) comprising an amino acid sequence of SEQ ID NO:50 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:50; (h) comprising an amino acid sequence of SEQ ID NO:56 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:56; (i) comprises an amino acid sequence of SEQ ID NO:64 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:64; (j) comprising an amino acid sequence of SEQ ID NO:70 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:70; (k) comprising the amino acid sequence of SEQ ID NO:78 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:78; or (l) comprises an amino acid sequence of SEQ ID NO:84 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:84; The polypeptide.

2. (a) The antigen-binding variable region of claim 1(a), (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:20 and 21, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:20 and 21, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:18 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:18; or (b) The antigen-binding variable region of claim 1(b), (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:26 and 27, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:26 and 27, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:24 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:24; or (c) The antigen-binding variable region of claim 1(c), (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:6 and 7, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:6 and 7, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:4 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:4; or (d) The antigen-binding variable region of claim 1(d) (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:12 and 13, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:12 and 13, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:10 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:10; or (e) The antigen-binding variable region of claim 1(e), (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:34 and 35, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:34 and 35, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:32 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:32; or (f) The antigen-binding variable region of claim 1(f) (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:40 and 41, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:40 and 41, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:38 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:38; or (g) The antigen-binding variable region of claim 1(g), (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:48 and 49, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:48 and 49, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:38 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:46; or (h) The antigen-binding variable region of claim 1(h), (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:54 and 55, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:54 and 55, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:52 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:52; or (i) The antigen-binding variable region of claim 1(i), (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:62 and 63, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:62 and 63, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:60 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:60; or (j) The antigen-binding variable region of claim 1(j) (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:68 and 69, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:68 and 69, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:66 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:66; or (k) The antigen-binding variable region of claim 1(k) (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:76 and 77, respectively, or having an amino acid sequence that is at least 80% sequence identical to SEQ ID NOs:76 and 77, respectively; and / or (ii) comprises the amino acid sequence of SEQ ID NO:74 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:74; or (l) The antigen-binding variable region of claim 1(l) (i) comprising CDR1, CDR2, and / or CDR3, optionally comprising CDR1 and / or CDR2 having the amino acid sequences of SEQ ID NOs:82 and 83, respectively, or having amino acid sequences that are at least 80% sequence identical to SEQ ID NOs:82 and 83, respectively; and / or (ii) comprises an amino acid sequence of SEQ ID NO:80 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:80; The polypeptide of claim 1.

3. A nucleic acid encoding the polypeptide of claim 1 or 2.

4. 1. An engineered T cell receptor (TCR) comprising a TCR-b polypeptide and a TCR-a polypeptide, (a) the TCR-a polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:22 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:22, and the TCR-b polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:28 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:28; or (b) the TCR-b polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:8 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:8, and the TCR-a polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:14 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:14; or (c) the TCR-a polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:36 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:36, and the TCR-b polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:42 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:42; or (d) the TCR-a polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:50 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:50, and the TCR-b polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:56 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:56; or (e) the TCR-a polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:64 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:64, and the TCR-b polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:70 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:70; or (f) the TCR-a polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:78 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:78, and the TCR-b polypeptide comprises a CDR3 having an amino acid sequence of SEQ ID NO:84 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:84; The engineered TCR.

5. 5. The TCR of claim 4, comprising a TCR-b polypeptide comprising a variable region comprising CDR1, CDR2, and CDR3, and a TCR-a polypeptide comprising a variable region comprising CDR1, CDR2, and CDR3, (a) the TCR-a polypeptide and the TCR-b polypeptide are as claimed in claim 4(a), (i) the TCR-a polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:20 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:20, and / or the TCR-b polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:26 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:26, and / or (ii) the TCR-a polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:21 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:21, and / or the TCR-b polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:27 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:27, and / or (iii) the TCR-a polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs:20, 21, and 22, respectively, and the TCR-b polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs:26, 27, and 28, respectively; and / or (iv) the TCR-a polypeptide comprises the amino acid sequence of SEQ ID NO:18 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:18, and the TCR-b polypeptide comprises the amino acid sequence of SEQ ID NO:24 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:24; or (b) the TCR-b polypeptide and the TCR-a polypeptide are as claimed in claim 4(b), (i) the TCR-b polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:6 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:6, and / or the TCR-a polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:12 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:12, and / or (ii) the TCR-b polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:7 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:7, and / or the TCR-a polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:13 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:13, and / or (iii) the TCR-b polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs:6, 7, and 8, respectively, and the TCR-a polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs:12, 13, and 14, respectively; and / or (iv) the TCR-b polypeptide comprises the amino acid sequence of SEQ ID NO:4 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:4, and the TCR-a polypeptide comprises the amino acid sequence of SEQ ID NO:10 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:10; or (c) The TCR-a polypeptide and the TCR-b polypeptide are as claimed in claim 4(c), (i) the TCR-a polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:34 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:34, and / or the TCR-b polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:40 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:40, and / or (ii) the TCR-a polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:35 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:35, and / or the TCR-b polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:41 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:41, and / or (iii) the TCR-a polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs:34, 35, and 36, respectively, and the TCR-b polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs:40, 41, and 42, respectively; and / or (iv) the TCR-a polypeptide comprises the amino acid sequence of SEQ ID NO:32 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:32, and the TCR-b polypeptide comprises the amino acid sequence of SEQ ID NO:38 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:38; or (d) The TCR-a polypeptide and the TCR-b polypeptide are as claimed in claim 4(d), (i) the TCR-a polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:48 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:48, and / or the TCR-b polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:54 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:54, and / or (ii) the TCR-a polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:49 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:49, and / or the TCR-b polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:55 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:55, and / or (iii) the TCR-a polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs: 48, 49, and 50, respectively, and the TCR-b polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs: 54, 55, and 56, respectively; and / or (iv) the TCR-a polypeptide comprises the amino acid sequence of SEQ ID NO:46, or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:46, and the TCR-b polypeptide comprises the amino acid sequence of SEQ ID NO:52, or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:52; or (e) The TCR-a polypeptide and the TCR-b polypeptide are as claimed in claim 4(e), (i) the TCR-a polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:62 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:62, and / or the TCR-b polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:68 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:68, and / or (ii) the TCR-a polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:63 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:63, and / or the TCR-b polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:69 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:69, and / or (iii) the TCR-a polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs:62, 63, and 64, respectively, and the TCR-b polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs:68, 69, and 70, respectively; and / or (iv) the TCR-a polypeptide comprises the amino acid sequence of SEQ ID NO:60 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:60, and the TCR-b polypeptide comprises the amino acid sequence of SEQ ID NO:66 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:66; or (f) The TCR-a polypeptide and the TCR-b polypeptide are as claimed in claim 4(f), (i) the TCR-a polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:76 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:76, and / or the TCR-b polypeptide comprises a CDR1 having an amino acid sequence of SEQ ID NO:82 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:82, and / or (ii) the TCR-a polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:77 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:77, and / or the TCR-b polypeptide comprises a CDR2 having an amino acid sequence of SEQ ID NO:83 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:83, and / or (iii) the TCR-a polypeptide comprises CDR1, CDR2, and CDR3 having the amino acid sequences of SEQ ID NOs:76, 77, and 78, respectively, and the TCR-b polypeptide comprises CDR1, CDR3, and CDR3 having the amino acid sequences of SEQ ID NOs:82, 83, and 84, respectively; and / or (iv) the TCR-a polypeptide comprises an amino acid sequence of SEQ ID NO:74 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:74, and the TCR-b polypeptide comprises an amino acid sequence of SEQ ID NO:80 or an amino acid sequence having at least 70% sequence identity to SEQ ID NO:80; The TCR.

6. A fusion protein comprising the TCR of claim 4 or 5 and a CD3 binding region, Optionally, the fusion protein, wherein the CD3 binding region comprises a CD3-specific antigen-binding fragment (Fab), a single chain variable fragment (scFv), a single domain antibody, or a single chain antibody.

7. (a) a nucleic acid encoding a TCR-a polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:22 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:22 and / or a TCR-b polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:28 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:28; or (b) a nucleic acid encoding a TCR-b polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:8 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:8, and / or a TCR-a polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:14 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:14; or (c) a nucleic acid encoding a TCR-a polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:36 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:36 and / or a TCR-b polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:42 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:42; or (d) a nucleic acid encoding a TCR-a polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:50 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:50, and / or a TCR-b polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:56 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:56; or (e) a nucleic acid encoding a TCR-a polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:64 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:64 and / or a TCR-b polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:70 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:70; or (f) a nucleic acid encoding a TCR-a polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:78 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:78 and / or a TCR-b polypeptide comprising a CDR3 having an amino acid sequence of SEQ ID NO:84 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:

84.

8. 8. The nucleic acid of claim 7, 7. The nucleic acid of claim 7(a), which encodes: (a) a TCR-a polypeptide comprising CDR1, CDR2, and CDR3 and / or a TCR-b polypeptide comprising CDR1, CDR2, and CDR3, and optionally (i) a nucleic acid encoding a TCR-b comprising a CDR1 having an amino acid sequence of SEQ ID NO:20 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:20, and / or a TCR-a comprising a CDR1 having an amino acid sequence of SEQ ID NO:26 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:26; and / or (ii) a nucleic acid encoding a TCR-a comprising a CDR2 having an amino acid sequence of SEQ ID NO:21 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:21 and / or a TCR-b comprising a CDR2 having an amino acid sequence of SEQ ID NO:27 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:27; and / or (iii) a nucleic acid encoding a TCR-a variable region having an amino acid sequence of SEQ ID NO:18 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:18 and / or a TCR-b variable region having an amino acid sequence of SEQ ID NO:24 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:24, and optionally a nucleic acid encoding a TCR-a polypeptide chain having an amino acid sequence of SEQ ID NO:17 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:17 and / or a TCR-b polypeptide chain having an amino acid sequence of SEQ ID NO:23 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:23, and optionally a nucleic acid comprising SEQ ID NO:15 or a fragment thereof; or (b) a nucleic acid according to claim 7(b) encoding a TCR-b polypeptide comprising CDR1, CDR2 and CDR3 and / or a TCR-a polypeptide comprising CDR1, CDR2 and CDR3, optionally comprising: (i) a nucleic acid encoding a TCR-b comprising a CDR1 having an amino acid sequence of SEQ ID NO:6 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:6, and / or a TCR-a comprising a CDR1 having an amino acid sequence of SEQ ID NO:12 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:12, and / or (ii) a nucleic acid encoding a TCR-b comprising a CDR2 having an amino acid sequence of SEQ ID NO:7 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:7, and / or a TCR-a comprising a CDR2 having an amino acid sequence of SEQ ID NO:13 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:13; and / or (iii) a nucleic acid encoding a TCR-b variable region having an amino acid sequence of SEQ ID NO:4 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:4 and / or a TCR-a variable region having an amino acid sequence of SEQ ID NO:10 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:10, and optionally a nucleic acid encoding a TCR-b polypeptide chain having an amino acid sequence of SEQ ID NO:3 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:3 and / or a TCR-a polypeptide chain having an amino acid sequence of SEQ ID NO:9 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:9, and optionally a nucleic acid comprising SEQ ID NO:1 or a fragment thereof; or (c) The nucleic acid of claim 7(c) encoding a TCR-a polypeptide comprising CDR1, CDR2, and CDR3 and / or a TCR-b polypeptide comprising CDR1, CDR2, and CDR3, optionally comprising: (i) a nucleic acid encoding a TCR-a comprising a CDR1 having an amino acid sequence of SEQ ID NO:34 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:34 and / or a TCR-b comprising a CDR1 having an amino acid sequence of SEQ ID NO:40 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:40; and / or (ii) a nucleic acid encoding a TCR-a comprising a CDR2 having an amino acid sequence of SEQ ID NO:35 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:35, and / or a TCR-b comprising a CDR2 having an amino acid sequence of SEQ ID NO:41 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:41; and / or (iii) a nucleic acid encoding a TCR-a variable region having an amino acid sequence of SEQ ID NO:32 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:32 and / or a TCR-b variable region having an amino acid sequence of SEQ ID NO:38 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:38, optionally encoding a TCR-a polypeptide chain having an amino acid sequence of SEQ ID NO:31 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:31 and / or a TCR-b polypeptide chain having an amino acid sequence of SEQ ID NO:37 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:37, and optionally further comprising SEQ ID NO:29 or a fragment thereof; or (d) the nucleic acid of claim 7(d) encoding a TCR-a polypeptide comprising CDR1, CDR2, and CDR3 and / or a TCR-b polypeptide comprising CDR1, CDR2, and CDR3, optionally comprising: (i) a nucleic acid encoding a TCR-a comprising a CDR1 having an amino acid sequence of SEQ ID NO:48 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:48, and / or a TCR-b comprising a CDR1 having an amino acid sequence of SEQ ID NO:54 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:54; and / or (ii) a nucleic acid encoding a TCR-a comprising a CDR2 having an amino acid sequence of SEQ ID NO:49 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:49 and / or a TCR-b comprising a CDR2 having an amino acid sequence of SEQ ID NO:55 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:55; and / or (iii) a nucleic acid encoding a TCR-a variable region having an amino acid sequence of SEQ ID NO:46 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:46 and / or a TCR-b variable region having an amino acid sequence of SEQ ID NO:52 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:52, optionally encoding a TCR-a polypeptide chain having an amino acid sequence of SEQ ID NO:45 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:45 and / or a TCR-b polypeptide chain having an amino acid sequence of SEQ ID NO:51 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:51, and optionally comprising SEQ ID NO:43 or a fragment thereof; (e) The nucleic acid of claim 7(e) encoding a TCR-a polypeptide comprising CDR1, CDR2, and CDR3 and / or a TCR-b polypeptide comprising CDR1, CDR2, and CDR3, optionally comprising: (i) a nucleic acid encoding a TCR-a comprising a CDR1 having an amino acid sequence of SEQ ID NO:62 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:62 and / or a TCR-b comprising a CDR1 having an amino acid sequence of SEQ ID NO:68 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:68; and / or (ii) a nucleic acid encoding a TCR-a comprising a CDR2 having an amino acid sequence of SEQ ID NO:63 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:63 and / or a TCR-b comprising a CDR2 having an amino acid sequence of SEQ ID NO:69 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:69; and / or (iii) a nucleic acid encoding a TCR-a variable region having an amino acid sequence of SEQ ID NO:60 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:60 and / or a TCR-b variable region having an amino acid sequence of SEQ ID NO:66 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:66, optionally encoding a TCR-a polypeptide chain having an amino acid sequence of SEQ ID NO:59 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:59 and / or a TCR-b polypeptide chain having an amino acid sequence of SEQ ID NO:65 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:65, and optionally further comprising SEQ ID NO:57 or a fragment thereof; or (f) The nucleic acid of claim 7(f) encoding a TCR-a polypeptide comprising CDR1, CDR2, and CDR3 and / or a TCR-b polypeptide comprising CDR1, CDR2, and CDR3, optionally comprising: (i) encoding a TCR-a comprising a CDR1 having an amino acid sequence of SEQ ID NO:76 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:76 and / or a TCR-b comprising a CDR1 having an amino acid sequence of SEQ ID NO:82 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:82; and / or (ii) encoding a TCR-a comprising a CDR2 having an amino acid sequence of SEQ ID NO:77 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:77, and / or a TCR-b comprising a CDR2 having an amino acid sequence of SEQ ID NO:83 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO:83; and / or (iii) encoding a TCR-a variable region having an amino acid sequence of SEQ ID NO:74 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:74 and / or a TCR-b variable region having an amino acid sequence of SEQ ID NO:80 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:80, optionally encoding a TCR-a polypeptide chain having an amino acid sequence of SEQ ID NO:73 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:73 and / or a TCR-b polypeptide chain having an amino acid sequence of SEQ ID NO:79 or an amino acid sequence that has at least 70% sequence identity to SEQ ID NO:79, and optionally further comprising SEQ ID NO:71 or a fragment thereof; The nucleic acid.

9. 9. The nucleic acid according to claim 7 or 8, (i) containing the TCR-a (TRA) and TCR-b (TRB) genes; and / or (ii) is polycistronic, optionally containing an internal ribosome entry site (IRES) or a 2A cleavable linker, and / or (iii) comprises cDNA encoding the TCR-a and / or TCR-b genes; and / or (iv) further encoding a polypeptide comprising a CD3 binding region, optionally wherein the CD3 binding region comprises a CD3-specific antigen-binding fragment (Fab), a single chain variable fragment (scFv), a single domain antibody, or a single chain antibody; The nucleic acid.

10. A nucleic acid vector comprising a nucleic acid according to any one of claims 3 and 7 to 9, optionally comprising: (a) comprising a promoter directing expression of the nucleic acid, and optionally, the promoter comprises a murine stem cell virus (MSCV) promoter; and / or (b) comprising the TCR-a and TCR-b genes; The vector.

11. A cell comprising a polypeptide according to claim 1 or 2, a TCR according to claim 4 or 5, a fusion protein according to claim 6, a nucleic acid according to any one of claims 3 and 7 to 9, or a vector according to claim 10.

12. The cell of claim 11, (i) comprising stem cells, progenitor cells, immune cells, or natural killer (NK) cells, optionally comprising hematopoietic stem or progenitor cells, T cells, cells differentiated from mesenchymal stem cells (MSCs), or induced pluripotent stem cells (iPSCs); and / or (ii) isolated or derived from peripheral blood mononuclear cells (PBMCs); and / or (iii) Cytotoxic T lymphocytes (CTL), CD8 + T cells, CD4 + and / or, the T cells include T cells, invariant NK T (iNKT) cells, gamma-delta T cells, NKT cells, or regulatory T cells. (iv) isolated from a cancer patient; The cells.

13. A composition comprising a polypeptide according to claim 1 or 2, a TCR according to claim 4 or 5, a fusion protein according to claim 6, a nucleic acid according to any one of claims 3 and 7 to 9, or a vector according to claim 10, or a cell according to claim 11 or 12, Optionally, the composition has been determined to be serum-free, mycoplasma-free, endotoxin-free, and / or sterile.

14. A method for producing an engineered cell, comprising the step of introducing a nucleic acid according to any one of claims 3 and 7 to 9 or a vector according to claim 10 into a cell, Optionally, the method further comprises culturing the cells in a medium, incubating the cells under conditions that allow the cells to divide, screening the cells, and / or freezing the cells.

15. 1. A composition for use in a method for treating cancer in a subject, comprising: The method comprises administering to a subject in need thereof a composition according to claim 13 or a cell according to claim 11 or 12, and optionally (i) the cancer includes lung cancer; and / or (ii) the subject has previously undergone treatment for cancer; and, optionally, The subject has been determined to be resistant to a previous treatment, and / or (iii) further comprising administering a further therapeutic regimen; and / or (iv) the cancer comprises stage I, II, III, or IV cancer; and / or (v) the cancer comprises metastatic and / or recurrent cancer; and / or (vi) the subject is HLA-A31 or HLA-A33 positive and / or has been determined to be HLA-A31 or HLA-A33 positive; and / or (vii) the subject carries an EGFR L858R mutation, and / or (viii) the cancer comprises EGFR L858R-positive cancer; and / or (ix) the lung cancer includes lung adenocarcinoma, non-small cell lung cancer, squamous cell lung cancer, or small cell lung cancer; The composition.